00016109502020Q1FALSE--12-31P1DP1Y00016109502020-01-012020-03-31xbrli:shares00016109502020-04-24iso4217:USD00016109502019-01-012019-03-31iso4217:USDxbrli:shares00016109502020-03-3100016109502019-12-3100016109502018-12-3100016109502019-03-310001610950us-gaap:AccountingStandardsUpdate201613Member2019-12-310001610950us-gaap:AccountingStandardsUpdate201613Member2018-12-310001610950us-gaap:RetainedEarningsMember2019-12-310001610950us-gaap:RetainedEarningsMember2018-12-310001610950us-gaap:CommonStockMember2019-12-310001610950us-gaap:CommonStockMember2018-12-310001610950us-gaap:CommonStockMember2020-01-012020-03-310001610950us-gaap:CommonStockMember2019-01-012019-03-310001610950us-gaap:CommonStockMember2020-03-310001610950us-gaap:CommonStockMember2019-03-310001610950us-gaap:AdditionalPaidInCapitalMember2019-12-310001610950us-gaap:AdditionalPaidInCapitalMember2018-12-310001610950us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-310001610950us-gaap:AdditionalPaidInCapitalMember2019-01-012019-03-310001610950us-gaap:AdditionalPaidInCapitalMember2020-03-310001610950us-gaap:AdditionalPaidInCapitalMember2019-03-310001610950us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310001610950us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-310001610950us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-310001610950us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-03-310001610950us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-310001610950us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-03-310001610950us-gaap:RetainedEarningsMemberus-gaap:AccountingStandardsUpdate201613Member2019-12-310001610950us-gaap:RetainedEarningsMemberus-gaap:AccountingStandardsUpdate201613Member2018-12-310001610950us-gaap:RetainedEarningsMember2020-03-310001610950us-gaap:RetainedEarningsMember2019-03-310001610950us-gaap:RetainedEarningsMember2020-01-012020-03-310001610950us-gaap:RetainedEarningsMember2019-01-012019-03-31synh:segment0001610950us-gaap:AccountingStandardsUpdate201613Member2020-01-010001610950synh:ClinicalSolutionsSegmentMember2019-12-310001610950synh:CommercialSolutionsSegmentMember2019-12-310001610950synh:ClinicalSolutionsSegmentMember2020-01-012020-03-310001610950synh:CommercialSolutionsSegmentMember2020-01-012020-03-310001610950synh:ClinicalSolutionsSegmentMember2020-03-310001610950synh:CommercialSolutionsSegmentMember2020-03-310001610950us-gaap:AccumulatedTranslationAdjustmentMember2019-12-310001610950us-gaap:AccumulatedTranslationAdjustmentMember2018-12-310001610950us-gaap:AccumulatedTranslationAdjustmentMember2020-01-012020-03-310001610950us-gaap:AccumulatedTranslationAdjustmentMember2019-01-012019-03-310001610950us-gaap:AccumulatedTranslationAdjustmentMember2020-03-310001610950us-gaap:AccumulatedTranslationAdjustmentMember2019-03-310001610950us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-12-310001610950us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2018-12-310001610950us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-01-012020-03-310001610950us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2019-01-012019-03-310001610950us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-03-310001610950us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2019-03-310001610950us-gaap:SecuredDebtMembersynh:A2017CreditAgreementAmendmentNo2TermLoanADueMarch2024Member2020-03-310001610950us-gaap:SecuredDebtMembersynh:A2017CreditAgreementAmendmentNo2TermLoanADueMarch2024Member2019-12-310001610950us-gaap:SecuredDebtMembersynh:A2017CreditAgreementAmendmentNo2TermLoanBDueAugust2024Member2020-03-310001610950us-gaap:SecuredDebtMembersynh:A2017CreditAgreementAmendmentNo2TermLoanBDueAugust2024Member2019-12-310001610950us-gaap:SecuredDebtMemberus-gaap:RevolvingCreditFacilityMember2019-03-310001610950us-gaap:SecuredDebtMemberus-gaap:RevolvingCreditFacilityMember2019-12-310001610950synh:AccountsReceivableSecuritizationMembersynh:AccountsReceivableFinancingAgreementDueSeptember2021Memberus-gaap:SecuredDebtMember2020-03-310001610950synh:AccountsReceivableSecuritizationMembersynh:AccountsReceivableFinancingAgreementDueSeptember2021Memberus-gaap:SecuredDebtMember2019-12-310001610950us-gaap:SecuredDebtMember2020-03-310001610950us-gaap:SecuredDebtMember2019-12-310001610950synh:TermLoanMemberus-gaap:SecuredDebtMembersynh:A2017CreditAgreementAmendmentNo2TermLoanADueMarch2024Member2020-03-310001610950synh:TermLoanMemberus-gaap:SecuredDebtMembersynh:A2017CreditAgreementTermLoanBDueAugust2024Member2020-03-310001610950us-gaap:RevolvingCreditFacilityMemberus-gaap:SecuredDebtMembersynh:A2017CreditAgreementAmendmentNo2RevolvingCreditFacilityDueMarch2024Member2020-03-310001610950us-gaap:SecuredDebtMembersynh:A2017CreditAgreementRevolvingCreditFacilityDueAugust2022Memberus-gaap:LetterOfCreditMember2020-03-310001610950us-gaap:SecuredDebtMembersynh:A2017CreditAgreementRevolvingCreditFacilityDueAugust2022Member2020-03-31xbrli:pure0001610950srt:SubsidiariesMembersynh:AccountsReceivableSecuritizationMemberus-gaap:SecuredDebtMembersynh:FederalFundsRateMembersynh:AccountsReceivableFinancingAgreementDueJune2020Member2020-01-012020-03-310001610950srt:SubsidiariesMember2020-01-012020-03-310001610950synh:AccountsReceivableSecuritizationMemberus-gaap:SecuredDebtMembersynh:AccountsReceivableFinancingAgreementDueJune2020Member2020-03-310001610950srt:SubsidiariesMembersynh:AccountsReceivableSecuritizationMemberus-gaap:SecuredDebtMembersynh:AccountsReceivableFinancingAgreementDueJune2020Member2020-03-310001610950synh:InterestRateSwapsExpiringOnJune302018AndMay142020Member2016-05-310001610950synh:InterestRateSwapsExpiringOnJune302018AndMay142020Member2020-03-310001610950synh:InterestRateSwapExpiredDecember312018Member2018-06-300001610950synh:InterestRateSwapExpiringJune302021Member2018-12-310001610950synh:InterestRateSwapExpiredDecember312018ExpiringJune302021Member2020-03-310001610950synh:InterestRateSwapExpiringMarch312023Member2020-03-310001610950srt:ScenarioForecastMembersynh:InterestRateSwapExpiringMarch312023Member2021-01-010001610950us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2020-03-310001610950us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2019-12-310001610950us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2020-03-310001610950us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2019-12-310001610950us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AccruedLiabilitiesMemberus-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2020-03-310001610950us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:AccruedLiabilitiesMemberus-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2019-12-310001610950us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2020-03-310001610950us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMember2019-12-310001610950us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-03-310001610950us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-03-310001610950us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-03-310001610950us-gaap:FairValueMeasurementsRecurringMember2020-03-310001610950us-gaap:FairValueMeasurementsRecurringMembersrt:PartnershipInterestMemberus-gaap:FairValueInputsLevel1Member2020-03-310001610950us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Membersrt:PartnershipInterestMember2020-03-310001610950us-gaap:FairValueMeasurementsRecurringMembersrt:PartnershipInterestMemberus-gaap:FairValueInputsLevel3Member2020-03-310001610950us-gaap:FairValueMeasurementsRecurringMembersrt:PartnershipInterestMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2020-03-310001610950us-gaap:FairValueMeasurementsRecurringMembersrt:PartnershipInterestMember2020-03-310001610950us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2020-03-310001610950us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2019-12-310001610950us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2019-12-310001610950us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2019-12-310001610950us-gaap:FairValueMeasurementsRecurringMember2019-12-310001610950us-gaap:FairValueMeasurementsRecurringMembersrt:PartnershipInterestMemberus-gaap:FairValueInputsLevel1Member2019-12-310001610950us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Membersrt:PartnershipInterestMember2019-12-310001610950us-gaap:FairValueMeasurementsRecurringMembersrt:PartnershipInterestMemberus-gaap:FairValueInputsLevel3Member2019-12-310001610950us-gaap:FairValueMeasurementsRecurringMembersrt:PartnershipInterestMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2019-12-310001610950us-gaap:FairValueMeasurementsRecurringMembersrt:PartnershipInterestMember2019-12-310001610950us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2019-12-310001610950us-gaap:FairValueMeasurementsNonrecurringMember2020-03-310001610950us-gaap:FairValueMeasurementsNonrecurringMember2019-12-310001610950us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:SecuredDebtMemberus-gaap:FairValueInputsLevel2Membersynh:A2017CreditAgreementAmendmentNo2TermLoanADueMarch2024Member2020-03-310001610950us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:SecuredDebtMemberus-gaap:FairValueInputsLevel2Membersynh:A2017CreditAgreementAmendmentNo2TermLoanADueMarch2024Member2020-03-310001610950us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:SecuredDebtMemberus-gaap:FairValueInputsLevel2Membersynh:A2017CreditAgreementAmendmentNo2TermLoanADueMarch2024Member2019-12-310001610950us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:SecuredDebtMemberus-gaap:FairValueInputsLevel2Membersynh:A2017CreditAgreementAmendmentNo2TermLoanADueMarch2024Member2019-12-310001610950us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:SecuredDebtMemberus-gaap:FairValueInputsLevel2Membersynh:A2017CreditAgreementAmendmentNo2TermLoanBDueAugust2024Member2020-03-310001610950us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:SecuredDebtMemberus-gaap:FairValueInputsLevel2Membersynh:A2017CreditAgreementAmendmentNo2TermLoanBDueAugust2024Member2020-03-310001610950us-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:SecuredDebtMemberus-gaap:FairValueInputsLevel2Membersynh:A2017CreditAgreementAmendmentNo2TermLoanBDueAugust2024Member2019-12-310001610950us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:SecuredDebtMemberus-gaap:FairValueInputsLevel2Membersynh:A2017CreditAgreementAmendmentNo2TermLoanBDueAugust2024Member2019-12-310001610950synh:InVentivMergerMemberus-gaap:EmployeeSeveranceMember2020-01-012020-03-310001610950synh:InVentivMergerMemberus-gaap:FacilityClosingMember2020-01-012020-03-310001610950us-gaap:EmployeeSeveranceMember2020-01-012020-03-310001610950us-gaap:FacilityClosingMember2020-01-012020-03-310001610950us-gaap:OtherRestructuringMember2020-01-012020-03-310001610950us-gaap:BusinessRestructuringReservesMemberus-gaap:EmployeeSeveranceMember2019-12-310001610950us-gaap:OtherRestructuringMemberus-gaap:BusinessRestructuringReservesMember2019-12-310001610950us-gaap:BusinessRestructuringReservesMember2019-12-310001610950us-gaap:BusinessRestructuringReservesMemberus-gaap:EmployeeSeveranceMember2020-01-012020-03-310001610950us-gaap:OtherRestructuringMemberus-gaap:BusinessRestructuringReservesMember2020-01-012020-03-310001610950us-gaap:BusinessRestructuringReservesMember2020-01-012020-03-310001610950us-gaap:BusinessRestructuringReservesMemberus-gaap:EmployeeSeveranceMember2020-03-310001610950us-gaap:OtherRestructuringMemberus-gaap:BusinessRestructuringReservesMember2020-03-310001610950us-gaap:BusinessRestructuringReservesMember2020-03-3100016109502018-02-2600016109502019-12-050001610950us-gaap:CommonStockMember2018-03-012018-03-310001610950us-gaap:CommonStockMember2018-04-012018-04-300001610950us-gaap:CommonStockMember2019-01-012019-01-310001610950us-gaap:CommonStockMember2019-02-012019-02-280001610950us-gaap:CommonStockMember2019-06-012019-06-300001610950us-gaap:CommonStockMember2019-08-012019-08-310001610950us-gaap:CommonStockMember2020-03-012020-03-310001610950us-gaap:CommonStockMember2018-03-012020-03-310001610950us-gaap:CommonStockMember2020-03-310001610950us-gaap:StockCompensationPlanMember2020-01-012020-03-310001610950us-gaap:StockCompensationPlanMember2019-01-012019-03-310001610950synh:AntidilutiveSecuritiesExcludedDuetoReportingofNetLossDuringthePeriodMemberus-gaap:StockCompensationPlanMember2020-01-012020-03-310001610950synh:AntidilutiveSecuritiesExcludedDuetoReportingofNetLossDuringthePeriodMemberus-gaap:StockCompensationPlanMember2019-01-012019-03-310001610950srt:MinimumMember2020-01-012020-03-310001610950srt:MaximumMember2020-01-012020-03-310001610950synh:ClinicalSolutionsSegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-03-310001610950synh:ClinicalSolutionsSegmentMemberus-gaap:OperatingSegmentsMember2019-01-012019-03-310001610950synh:CommercialSolutionsSegmentMemberus-gaap:OperatingSegmentsMember2020-01-012020-03-310001610950synh:CommercialSolutionsSegmentMemberus-gaap:OperatingSegmentsMember2019-01-012019-03-310001610950us-gaap:OperatingSegmentsMember2020-01-012020-03-310001610950us-gaap:OperatingSegmentsMember2019-01-012019-03-310001610950us-gaap:CorporateNonSegmentMembersynh:CostofServicesMember2020-01-012020-03-310001610950us-gaap:CorporateNonSegmentMembersynh:CostofServicesMember2019-01-012019-03-310001610950us-gaap:CorporateNonSegmentMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-03-310001610950us-gaap:CorporateNonSegmentMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2019-01-012019-03-310001610950us-gaap:CorporateNonSegmentMember2020-01-012020-03-310001610950us-gaap:CorporateNonSegmentMember2019-01-012019-03-310001610950srt:NorthAmericaMember2020-01-012020-03-310001610950srt:NorthAmericaMember2019-01-012019-03-310001610950us-gaap:EMEAMember2020-01-012020-03-310001610950us-gaap:EMEAMember2019-01-012019-03-310001610950srt:AsiaPacificMember2020-01-012020-03-310001610950srt:AsiaPacificMember2019-01-012019-03-310001610950srt:LatinAmericaMember2020-01-012020-03-310001610950srt:LatinAmericaMember2019-01-012019-03-310001610950country:US2020-01-012020-03-310001610950country:US2019-01-012019-03-310001610950country:USus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-01-012020-03-310001610950country:USus-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMember2019-01-012019-03-310001610950srt:NorthAmericaMember2020-03-310001610950srt:NorthAmericaMember2019-12-310001610950us-gaap:EMEAMember2020-03-310001610950us-gaap:EMEAMember2019-12-310001610950srt:AsiaPacificMember2020-03-310001610950srt:AsiaPacificMember2019-12-310001610950srt:LatinAmericaMember2020-03-310001610950srt:LatinAmericaMember2019-12-310001610950country:US2020-03-310001610950country:US2019-12-310001610950srt:AffiliatedEntityMember2019-01-012019-03-310001610950srt:AffiliatedEntityMember2020-03-31synh:numberOfAction0001610950synh:BermudezAndVaitkuvieneActionsMemberus-gaap:PendingLitigationMember2017-12-012017-12-010001610950synh:BermudezAndVaitkuvieneActionsMemberus-gaap:PendingLitigationMember2018-01-302018-01-300001610950synh:InVentivMergerMemberus-gaap:FairValueMeasurementsRecurringMember2020-03-310001610950synh:InVentivMergerMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001610950synh:KinapseTopcoLimitedMember2019-12-310001610950synh:KinapseTopcoLimitedMember2019-03-31



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 

FORM 10-Q 
(Mark One)
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2020
or
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from            to            .
Commission File Number: 001-36730
SYNEOS HEALTH, INC.
(Exact name of registrant as specified in its charter)
Delaware   27-3403111
(State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification No.)
1030 Sync Street, Morrisville, North Carolina 27560-5468
(Address of principal executive offices and Zip Code)
(919) 876-9300
(Registrant’s telephone number, including area code)
N/A
(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
                Class A Common Stock, $0.01 par value per share SYNH The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐
Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. 
Large accelerated filer   ☒    Accelerated filer   ☐
Non-accelerated filer   ☐    Smaller reporting company   ☐
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  ☐ No  ☒
As of April 24, 2020, there were approximately 104,169,107 shares of the registrant’s common stock outstanding.


Table of Contents



SYNEOS HEALTH, INC.
FORM 10-Q
TABLE OF CONTENTS
Page
Item 1.
3
3
4
5
6
7
8
Item 2.
25
Item 3.
39
Item 4.
40
Item 1.
41
Item 1A.
43
Item 2.
44
Item 5.
45
Item 6.
46
47

2


Table of Contents


PART I. FINANCIAL INFORMATION
Item 1. Financial Statements.

SYNEOS HEALTH, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

Three Months Ended March 31,
2020 2019
(in thousands, except per share data)
Revenue $ 1,163,355    $ 1,119,006   
Costs and operating expenses:
Direct costs (exclusive of depreciation and amortization) 924,014    886,802   
Selling, general, and administrative expenses 117,970    113,117   
Restructuring and other costs 8,720    14,413   
Transaction and integration-related expenses 7,577    16,658   
Depreciation 17,225    19,571   
Amortization 38,882    41,629   
Total operating expenses 1,114,388    1,092,190   
Income from operations 48,967    26,816   
Other (income) expense, net:
Interest income (336)   (1,502)  
Interest expense 26,458    34,630   
Loss on extinguishment of debt —    4,355   
Other (income) expense, net (18,930)   8,921   
Total other expense, net 7,192    46,404   
Income (loss) before provision for income taxes 41,775    (19,588)  
Income tax expense 8,201    10,416   
Net income (loss) $ 33,574    $ (30,004)  
Earnings (loss) per share:
Basic $ 0.32    $ (0.29)  
Diluted $ 0.32    $ (0.29)  
Weighted average common shares outstanding:
Basic 104,265    103,365   
Diluted 105,642    103,365   

The accompanying notes are an integral part of these condensed consolidated financial statements.
3


Table of Contents

SYNEOS HEALTH, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(Unaudited)

Three Months Ended March 31,
2020 2019
(in thousands)
Net income (loss) $ 33,574    $ (30,004)  
Unrealized loss on derivative instruments, net of income tax benefit of $(6,639) and $(95), respectively
(10,730)   (4,216)  
Foreign currency translation adjustments, net of income tax expense of $0 and $0, respectively
(48,788)   20,604   
Comprehensive loss $ (25,944)   $ (13,616)  

The accompanying notes are an integral part of these condensed consolidated financial statements.


4


Table of Contents

SYNEOS HEALTH, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
March 31, 2020 December 31, 2019
(in thousands, except par value)
ASSETS    
Current assets:    
Cash, cash equivalents, and restricted cash $ 335,960    $ 163,689   
Accounts receivable and unbilled services, net 1,340,648    1,303,641   
Prepaid expenses and other current assets 97,929    94,834   
Total current assets 1,774,537    1,562,164   
Property and equipment, net 195,620    203,926   
Operating lease right-of-use assets 218,437    218,531   
Goodwill 4,323,436    4,350,380   
Intangible assets, net 925,389    973,081   
Deferred income tax assets 34,239    37,012   
Other long-term assets 118,634    108,701   
Total assets $ 7,590,292    $ 7,453,795   
LIABILITIES AND SHAREHOLDERS' EQUITY          
Current liabilities:          
Accounts payable $ 112,312    $ 136,686   
Accrued expenses 504,351    568,911   
Deferred revenue 689,672    696,907   
Current portion of operating lease obligations 40,130    38,055   
Current portion of finance lease obligations 17,044    17,777   
Current portion of long-term debt 77,500    58,125   
Total current liabilities 1,441,009    1,516,461   
Long-term debt 2,831,722    2,550,395   
Operating lease long-term obligations 215,375    218,343   
Finance lease long-term obligations 32,077    36,914   
Deferred income tax liabilities 8,989    11,101   
Other long-term liabilities 83,198    90,927   
Total liabilities 4,612,370    4,424,141   
Commitments and contingencies (Note 15)
Shareholders' equity:          
Preferred stock, $0.01 par value; 30,000 shares authorized, 0 shares issued and outstanding at March 31, 2020 and December 31, 2019
—    —   
Common stock, $0.01 par value; 600,000 shares authorized, 104,161 and 103,866 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively
1,042    1,039   
Additional paid-in capital 3,430,740    3,441,471   
Accumulated other comprehensive loss, net of taxes (131,111)   (71,593)  
Accumulated deficit (322,749)   (341,263)  
Total shareholders' equity 2,977,922    3,029,654   
Total liabilities and shareholders' equity $ 7,590,292    $ 7,453,795   

The accompanying notes are an integral part of these condensed consolidated financial statements.
5


Table of Contents

SYNEOS HEALTH, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
Three Months Ended March 31,
2020 2019
(In thousands)
Cash flows from operating activities:
Net income (loss) $ 33,574    $ (30,004)  
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization 56,107    61,200   
Share-based compensation 15,998    14,267   
Provision for doubtful accounts 271    1,302   
Provision for deferred income taxes 8,159    1,544   
Foreign currency transaction gains (15,019)   (77)  
Fair value adjustment of contingent obligations (4,095)   724   
Loss on extinguishment of debt —    4,355   
Other non-cash items 1,104    (643)  
Changes in operating assets and liabilities:
Accounts receivable, unbilled services, and deferred revenue (53,078)   (25,471)  
Accounts payable and accrued expenses (66,426)   (26,682)  
Other assets and liabilities (15,202)   (13,821)  
Net cash used in operating activities (38,607)   (13,306)  
Cash flows from investing activities:
Purchases of property and equipment (11,870)   (11,445)  
Investments in unconsolidated affiliates (6,750)   —   
Net cash used in investing activities (18,620)   (11,445)  
Cash flows from financing activities:
Proceeds from issuance of long-term debt, net of discount —    183,195   
Payments of debt financing costs —    (184)  
Repayments of long-term debt —    (216,136)  
Proceeds from accounts receivable financing agreement 6,600    26,500   
Repayments of accounts receivable financing agreement (6,600)   —   
Proceeds from revolving line of credit 300,000    —   
Payments of contingent consideration related to business combinations (26,592)   (8)  
Payments of finance leases (4,674)   (1,274)  
Payments for repurchases of common stock (32,029)   (26,616)  
Proceeds from exercises of stock options 12,358    19,724   
Payments related to tax withholdings for share-based compensation (19,145)   (11,539)  
Net cash provided by (used in) financing activities 229,918    (26,338)  
Effect of exchange rate changes on cash, cash equivalents, and restricted cash (420)   3,078   
Net change in cash, cash equivalents, and restricted cash 172,271    (48,011)  
Cash, cash equivalents, and restricted cash - beginning of period 163,689    155,932   
Cash, cash equivalents, and restricted cash - end of period $ 335,960    $ 107,921   

The accompanying notes are an integral part of these condensed consolidated financial statements.
6


Table of Contents

SYNEOS HEALTH, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
(Unaudited)
Three Months Ended March 31,
2020 2019
(In thousands)
Shareholders' equity, beginning balance $ 3,029,654    $ 2,856,144   
Impact from adoption of ASU 2016-13 (2,771)   —   
Shareholders' equity, adjusted beginning balance 3,026,883    2,856,144   
Common stock:
Beginning balance 1,039    1,034   
Repurchases of common stock (6)   (7)  
Issuances of common stock 9    11   
Ending balance 1,042    1,038   
Additional paid-in capital:
Beginning balance 3,441,471    3,402,638   
Repurchases of common stock (19,734)   (22,132)  
Issuances of common stock (6,995)   8,180   
Share-based compensation 15,998    14,267   
Ending balance 3,430,740    3,402,953   
Accumulated other comprehensive loss:
Beginning balance (71,593)   (88,195)  
Unrealized loss on derivative instruments, net of taxes (10,730)   (4,216)  
Foreign currency translation adjustment, net of taxes (48,788)   20,604   
Ending balance (131,111)   (71,807)  
Accumulated deficit:
Beginning balance (341,263)   (459,333)  
Impact from adoption of ASU 2016-13 (2,771)   —   
Adjusted beginning balance (344,034)   (459,333)  
Repurchases of common stock (12,289)   (4,477)  
Net income (loss) 33,574    (30,004)  
Ending balance (322,749)   (493,814)  
Shareholders' equity, ending balance $ 2,977,922    $ 2,838,370   

The accompanying notes are an integral part of these condensed consolidated financial statements.
7


Table of Contents

SYNEOS HEALTH, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

1. Basis of Presentation and Changes in Significant Accounting Policies
Nature of Operations
Syneos Health, Inc. (the “Company”) is a global provider of end-to-end biopharmaceutical outsourcing solutions. The Company operates under two reportable segments, Clinical Solutions and Commercial Solutions, and derives its revenue through a suite of services designed to enhance its customers’ ability to successfully develop, launch, and market their products. The Company offers its solutions on both a standalone and integrated basis with biopharmaceutical development and commercialization services ranging from Phase I-IV clinical trial services to services associated with the commercialization of biopharmaceutical products. The Company’s customers include small, mid-sized, and large companies in the pharmaceutical, biotechnology, and medical device industries.
Unaudited Interim Financial Information
The Company prepared the accompanying unaudited condensed consolidated financial statements in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information. The significant accounting policies followed by the Company for interim financial reporting are consistent with the accounting policies followed for annual financial reporting.
The unaudited condensed consolidated financial statements, in management’s opinion, include all adjustments of a normal recurring nature necessary for a fair presentation. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the Securities and Exchange Commission (“SEC”) on February 20, 2020. The results of operations for the three months ended March 31, 2020 are not necessarily indicative of the results to be expected for the full year ending December 31, 2020 or any other future period. The unaudited condensed consolidated balance sheet at December 31, 2019 is derived from the amounts in the audited consolidated balance sheet included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019.
COVID-19 Pandemic
On March 11, 2020, the World Health Organization designated the outbreak of the novel strain of coronavirus known as COVID-19 as a global pandemic. Governments and businesses around the world have taken unprecedented actions to mitigate the spread of COVID-19, including, but not limited to, shelter-in-place orders, quarantines, significant restrictions on travel, as well as restrictions that prohibit many employees from going to work. Uncertainty with respect to the economic impacts of the pandemic has introduced significant volatility in the financial markets. The Company did not observe significant impacts on its business or results of operations for the three months ended March 31, 2020 due to the global emergence of COVID-19. While the extent to which COVID-19 impacts the Company’s future results will depend on future developments, the pandemic and associated economic impacts could result in a material impact to the Company’s future financial condition, results of operations and cash flows.




8



Recently Adopted Accounting Standards
In June 2016, the Financial Accounting Standards Board issued ASU No. 2016-13 ("ASU 2016-13"), Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments to modify the impairment model to utilize an expected loss methodology in place of the previous incurred loss methodology and require consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The Company adopted ASU 2016-13 on January 1, 2020, and recorded the impact of the adoption through a cumulative-effect adjustment to accumulated deficit. Results for reporting periods beginning on January 1, 2020 are presented under ASU No. 2016-13, while prior period amounts continue to be reported and disclosed in accordance with the Company's historical accounting treatment. Adoption of the new standard resulted in the recording of additional allowance for doubtful accounts of approximately $2.8 million as of January 1, 2020.
2. Financial Statement Details
Cash, Cash Equivalents, and Restricted Cash
Certain of the Company’s subsidiaries participate in a notional cash pooling arrangement to manage global liquidity requirements. The participants combine their cash balances in pooling accounts at the same financial institution with the ability to offset bank overdrafts of one participant against positive cash account balances held by another participant. The net cash balance related to this pooling arrangement is included in cash, cash equivalents, and restricted cash in the unaudited condensed consolidated balance sheets.
Accounts Receivable and Unbilled Services, net
Accounts receivable and unbilled services (including contract assets), net of allowance for doubtful accounts, consisted of the following (in thousands):
March 31, 2020 December 31, 2019
Accounts receivable billed $ 771,925    $ 787,652   
Accounts receivable unbilled 447,886    372,109   
Contract assets 128,769    149,261   
Less: Allowance for doubtful accounts (7,932)   (5,381)  
Accounts receivable and unbilled services, net $ 1,340,648    $ 1,303,641   
Accounts Receivable Factoring Arrangement
The Company has an accounts receivable factoring agreement to sell certain eligible unsecured trade accounts receivable, without recourse, to an unrelated third-party financial institution for cash. For the three months ended March 31, 2020 and 2019, the Company factored $36.2 million and $73.8 million, respectively, of trade accounts receivable on a non-recourse basis and received $36.0 million and $73.2 million, respectively, in cash proceeds from the sale. The fees associated with these transactions were insignificant.
9



Goodwill
The changes in the carrying amount of goodwill by segment for the three months ended March 31, 2020 were as follows (in thousands):
Clinical
Solutions (a) 		Commercial
Solutions (b) 		Total
Balance as of January 1, 2020 $ 2,784,952    $ 1,565,428    $ 4,350,380   
Impact of foreign currency translation (20,197)   (6,747)   (26,944)  
Balance as of March 31, 2020 $ 2,764,755    $ 1,558,681    $ 4,323,436   
(a) Accumulated impairment losses of $8.1 million associated with the Clinical Solutions segment were recorded prior to 2016 and related to the former Phase I Services segment, now a component of the Clinical Solutions segment. No impairment of goodwill was recorded for the three months ended March 31, 2020.
(b) Accumulated impairment losses of $8.0 million associated with the Commercial Solutions segment were recorded prior to 2015 and related to the former Global Consulting segment, now a component of the Commercial Solutions segment. No impairment of goodwill was recorded for the three months ended March 31, 2020.
During the three months ended March 31, 2020, the Company evaluated whether a triggering event had occurred because of the broad impacts of the COVID-19 pandemic. The Company expects the COVID-19 pandemic will negatively impact its full year 2020 results of operations. However, at this time, the Company does not believe there has been a significant change in the long-term fundamentals of its business. The Company has concluded a triggering event did not occur during the three months ended March 31, 2020, and, as a result, no interim impairment testing was required. The Company will continue to evaluate the impacts of the COVID-19 pandemic on its business. Depending on the extent to which future developments negatively impact the Company's results of operations and financial outlook, an interim impairment test may be required in the future.
Transaction and Integration-Related Expenses
Transaction and integration-related expenses consisted of the following (in thousands):
Three Months Ended March 31,
2020 2019
Professional fees $ 10,123    $ 12,846   
Debt modification and related expenses —    2,241   
Integration and personnel retention-related costs 1,549    847   
Fair value adjustments to contingent obligations (4,095)   724   
Total transaction and integration-related expenses $ 7,577    $ 16,658   
10



Accumulated Other Comprehensive Loss, Net of Taxes
Accumulated other comprehensive loss, net of taxes, consisted of the following (in thousands):
Three Months Ended March 31,
2020 2019
Beginning balance $ (71,593)   $ (88,195)  
Foreign currency translation:
  Beginning balance (56,757)   (80,955)  
    Other comprehensive (loss) income before reclassifications (48,788)   20,604   
  Ending balance (105,545)   (60,351)  
Derivative instruments:
  Beginning balance (14,836)   (7,240)  
    Other comprehensive loss before reclassifications (12,510)   (3,729)  
    Reclassification adjustments 1,780    487   
  Ending balance (25,566)   (11,456)  
Accumulated other comprehensive loss, net of taxes $ (131,111)   $ (71,807)  
Changes in accumulated other comprehensive loss consisted of the following (in thousands):
Three Months Ended March 31,
2020 2019
Foreign currency translation adjustments:
  Foreign currency translation adjustments, net of taxes $ (48,788)   $ 20,604   
Unrealized loss on derivative instruments:
    Unrealized loss during period, before taxes (19,783)   (3,805)  
    Income tax benefit (7,273)   (76)  
  Unrealized loss during period, net of taxes (12,510)   (3,729)  
    Reclassification adjustment, before taxes 2,414    506   
    Income tax expense 634    19   
  Reclassification adjustment, net of taxes 1,780    487   
  Total unrealized loss on derivative instruments, net of taxes (10,730)   (4,216)  
Total other comprehensive (loss) income, net of taxes $ (59,518)   $ 16,388   
Other (Income) Expense, Net
Other (income) expense, net consisted of the following (in thousands):
Three Months Ended March 31,
2020 2019
Net realized foreign currency (gain) loss $ (5,096)   $ 8,406   
Net unrealized foreign currency gain (15,019)   (77)  
Other, net 1,185    592   
Total other (income) expense, net $ (18,930)   $ 8,921   

11



3. Long-Term Debt Obligations
The Company’s debt obligations consisted of the following (in thousands):
March 31, 2020 December 31, 2019
Term Loan A due March 2024 $ 1,550,000    $ 1,550,000   
Term Loan B due August 2024 795,564    795,564   
Revolving credit facility due March 2024 300,000    —   
Accounts receivable financing agreement due September 2021 275,000    275,000   
Total debt obligations 2,920,564    2,620,564   
Less: Term loan original issuance discount (4,620)   (4,928)  
Less: Unamortized deferred issuance costs (6,722)   (7,116)  
Less: Current portion of debt (77,500)   (58,125)  
Total debt obligations, non-current portion $ 2,831,722    $ 2,550,395   
The Company is party to a credit agreement (as amended, the "Credit Agreement") for: (i) a $1.55 billion Term Loan A facility that matures on March 26, 2024 ("Term Loan A”); (ii) a $1.60 billion Term Loan B facility that matures on August 1, 2024 (“Term Loan B”); and (iii) a $600.0 million revolving credit facility (the “Revolver”) that matures on March 26, 2024.
During the three months ended March 31, 2020, the Company did not make any voluntary prepayments against Term Loan B. As a result of previous voluntary prepayments, the Company is not required to make a mandatory payment against the Term Loan B principal balance until maturity in August 2024. Additionally, during the three months ended March 31, 2020, the Company was not required to make mandatory principal payments towards Term Loan A. In March 2020, the Company drew $300.0 million on the Revolver.
Letters of Credit
The Revolver includes letters of credit ("LOCs") with a sublimit of $150.0 million. As of March 31, 2020, there were $300.0 million outstanding Revolver borrowings and $19.2 million of LOCs outstanding, leaving $280.8 million available borrowings under the Revolver.
The lease agreement for the corporate headquarters in Morrisville, North Carolina includes a provision that may require the Company to issue a LOC in certain amounts to the landlord based on the debt rating of the Company issued by Moody’s Investors Service (or other nationally-recognized debt rating agency). As of March 31, 2020 (and through the date of this filing), the Company’s debt rating was such that no LOC is currently required. Any required LOCs could be issued under the Company’s Revolver, and, if issued under the Revolver, would reduce its available borrowing capacity by the same amount accordingly.
Accounts Receivable Financing Agreement
The Company has an accounts receivable financing agreement (as amended) with a termination date of September 30, 2021, unless terminated earlier pursuant to its terms. Under this agreement, certain of the Company’s consolidated subsidiaries sell accounts receivable and unbilled services (including contract assets) balances to a wholly-owned, bankruptcy-remote special purpose entity (“SPE”). The Company has guaranteed the performance of the obligations of existing and future subsidiaries that sell and service the accounts receivable under this agreement. The available borrowing capacity varies monthly according to the levels of the Company’s eligible billed and unbilled services (including contract assets). Loans under this agreement will accrue interest at a reserve-adjusted LIBOR rate or a base rate equal to the higher of (i) the applicable lender’s prime rate and (ii) the federal funds rate plus 0.50%. The Company may prepay loans upon one business day prior notice and may terminate or reduce the facility limit of the accounts receivable financing agreement with 15 days’ prior notice.
12



As of March 31, 2020, the Company had $275.0 million of outstanding borrowings under the accounts receivable financing agreement, which are recorded in long-term debt on the accompanying unaudited condensed consolidated balance sheet. There was no remaining borrowing capacity under this agreement as of March 31, 2020.
As of March 31, 2020, the contractual maturities of the Company’s debt obligations (excluding leases) were as follows (in thousands):
Principal Interest (a)
2020 $ 58,125    $ 107,636   
2021 381,562    107,425   
2022 145,313    97,104   
2023 155,000    90,828   
2024 2,180,564    30,208   
Less: Deferred issuance costs (6,722)  
Less: Term loan original issuance discount (4,620)  
Total $ 2,909,222    $ 433,201   
(a) The interest payments on long-term debt in the above table are based on interest rates in effect as of March 31, 2020.

4. Derivatives
The Company has entered into various interest rate swaps to mitigate its exposure to changes in interest rates on its term loans.
In May 2016, the Company entered into interest rate swaps that had an initial notional value of $300.0 million and became effective on June 30, 2016. A portion of the interest rate swaps expired on June 30, 2018, and the remainder will expire on May 14, 2020. As of March 31, 2020, the remaining notional value of these interest rate swaps was $100.0 million.
In June 2018, the Company entered into interest rate swaps with multiple counterparties. The first interest rate swap had an aggregate notional value of $1.22 billion, began accruing interest on June 29, 2018, and expired on December 31, 2018. The second interest rate swap had an initial aggregate notional value of $1.01 billion, an effective date of December 31, 2018, and will expire on June 30, 2021. As of March 31, 2020, the remaining notional value of this interest rate swap was $940.3 million.
In March 2020, the Company entered into interest rate swaps with multiple counterparties. The interest rate swaps had an initial aggregate notional value of $549.2 million, increasing to $1.42 billion in 2021, an effective date of March 31, 2020, and will expire on March 31, 2023.
The fair values of the Company’s derivative financial instruments and the line items on the accompanying condensed consolidated balance sheets to which they were recorded were as follows (in thousands):
Balance Sheet Classification March 31, 2020 December 31, 2019
Interest rate swaps - current Prepaid expenses and other current assets $ —    $ 155   
Fair value of derivative assets $ —    $ 155   
Interest rate swaps - current Accrued expenses $ 24,770    $ 11,358   
Interest rate swaps - non-current Other long-term liabilities 9,898    6,095   
Fair value of derivative liabilities $ 34,668    $ 17,453   

13



5. Fair Value Measurements
Assets and Liabilities Carried at Fair Value
As of March 31, 2020 and December 31, 2019, the Company’s financial assets and liabilities carried at fair value included cash and cash equivalents, restricted cash, trading securities, accounts receivable, unbilled services (including contract assets), accounts payable, accrued expenses, deferred revenue, contingent obligations, liabilities under the accounts receivable financing agreement, and derivative instruments.
The fair values of cash and cash equivalents, restricted cash, accounts receivable, unbilled services (including contract assets), accounts payable, accrued expenses, deferred revenue, and the liabilities under the accounts receivable financing agreement approximate their respective carrying amounts because of the liquidity and short-term nature of these financial instruments.
Financial Instruments Subject to Recurring Fair Value Measurements
As of March 31, 2020, the fair values of the major classes of the Company’s assets and liabilities measured at fair value on a recurring basis were as follows (in thousands):
Level 1 Level 2 Level 3 Investments Measured
at Net Asset Value 		Total
Assets:
Trading securities (a) $ 18,081    $ —    $ —    $ —    $ 18,081   
Partnership interest (b) —    —    —    7,226    7,226   
Total assets $ 18,081    $ —    $ —    $ 7,226    $ 25,307   
Liabilities:
Derivative instruments (c) $ —    $ 34,668    $ —    $ —    $ 34,668   
Contingent obligations related to business combinations (d) —    —    6,380    —    6,380   
Total liabilities $ —    $ 34,668    $ 6,380    $ —    $ 41,048   
14



As of December 31, 2019, the fair values of the major classes of the Company’s assets and liabilities measured at fair value on a recurring basis were as follows (in thousands):
Level 1 Level 2 Level 3 Investments Measured
at Net Asset Value 		Total
Assets:
Trading securities (a)
$ 21,552    $ —    $ —    $ —    $ 21,552   
Partnership interest (b)
—    —    —    7,226    7,226   
Derivative instruments (c)
—    155    —    —    155   
Total assets $ 21,552    $ 155    $ —    $ 7,226    $ 28,933   
Liabilities:
Derivative instruments (c) $ —    $ 17,453    $ —    $ —    $ 17,453   
Contingent obligations related to business combinations (d)
—    —    37,324    —    37,324   
Total liabilities $ —    $ 17,453    $ 37,324    $ —    $ 54,777   
(a) Represents fair value of investments in mutual funds based on quoted market prices that are used to fund the liability associated with the Company's deferred compensation plan.
(b) The Company has committed to invest $21.5 million as a limited partner in two private equity funds. The private equity funds invest in opportunities in the healthcare and life sciences industry. As of March 31, 2020, the Company’s remaining unfunded commitment in the private equity funds was $14.6 million. The Company holds minor ownership interests (less than 3%) in each of the private equity funds and has determined that it does not exercise significant influence over the private equity funds' operating and finance activities. As the private equity funds do not have readily determinable fair values, the Company has estimated the fair values using each fund’s Net Asset Value, the amount by which the value of all assets exceeds all debt and liabilities, in accordance with ASC Topic 946, Financial Services – Investment Companies.
(c) Represents the fair value of interest rate swap arrangements (see "Note 4 - Derivatives" for further information).
(d) Represents the fair value of contingent consideration obligations related to business combinations. The fair value of these liabilities are determined based on the Company’s best estimate of the probable timing and amount of settlement.
The following table presents a reconciliation of changes in the carrying amount of contingent obligations classified as Level 3 for the three months ended March 31, 2020 (in thousands):
Balance as of December 31, 2019 $ 37,324   
Additions —   
Changes in fair value recognized in earnings (4,352)  
Payments (26,592)  
Balance as of March 31, 2020 $ 6,380   
During the three months ended March 31, 2020, there were no transfers of assets or liabilities between Level 1, Level 2, or Level 3 fair value measurements.
15



Financial Instruments Subject to Non-Recurring Fair Value Measurements
Certain assets, including goodwill and identifiable intangible assets, are carried on the accompanying condensed consolidated balance sheets at cost and, subsequent to initial recognition, are measured at fair value on a non-recurring basis when certain identified events or changes in circumstances that may have a significant adverse effect on the carrying values of these assets occur. These assets are classified as Level 3 fair value measurements within the fair value hierarchy. Goodwill is tested for impairment annually or more frequently if events or changes in circumstances indicate a triggering event has occurred. Intangible assets are tested for impairment upon the occurrence of certain triggering events. As of March 31, 2020 and December 31, 2019, assets carried on the condensed consolidated balance sheets and not remeasured to fair value on a recurring basis totaled $5.25 billion and $5.32 billion, respectively.
Fair Value Disclosures for Financial Instruments Not Carried at Fair Value
The estimated fair values of the outstanding term loans are determined based on quoted market prices. As these liabilities are not actively traded, they are classified as Level 2 fair value measurements. The estimated fair values of the Company’s outstanding term loans were as follows (in thousands):
March 31, 2020 December 31, 2019
Carrying Value (a)
Estimated Fair Value
Carrying Value (a)
Estimated Fair Value
Term Loan A due March 2024 $ 1,545,997    $ 1,443,750    $ 1,545,721    $ 1,550,000   
Term Loan B due August 2024 794,947    775,675    794,915    795,564   
(a) The carrying value of the term loan debt is shown net of original issue debt discounts.
6. Restructuring and Other Costs
Merger-Related Restructuring
During 2017, in connection with the merger (the "Merger") with Double Eagle Parent, Inc. ("inVentiv"), the parent company of inVentiv Health, Inc., the Company established a restructuring plan to eliminate redundant positions and reduce its facility footprint worldwide. The Company expects to continue the ongoing evaluations of its workforce and facilities infrastructure needs in an effort to optimize its resources. During the three months ended March 31, 2020, the Company recognized approximately $1.0 million of employee severance and benefits related costs and $0.6 million of facility closure and lease termination costs. The Company expects to continue to incur costs related to restructuring of its operations in order to achieve targeted synergies. However, the timing and the amount of these costs depend on various factors, including, but not limited to, identifying and realizing synergy opportunities and executing the integration of its combined operations.
Non Merger-Related Restructuring and Other Costs
During the three months ended March 31, 2020, the Company recognized approximately $6.6 million of employee severance and benefits related costs, $0.1 million of facility closure and lease termination costs, and $0.4 million of other costs in its continued efforts to optimize its resources worldwide. Additionally, the Company expects to incur incremental restructuring and other costs related to its cost savings initiatives in response to the COVID-19 pandemic.
16



Accrued Restructuring Liabilities
The following table summarizes activity related to the liabilities associated with restructuring and other costs during the three months ended March 31, 2020 (in thousands):
Employee
Severance Costs 		Other Costs Total
Balance as of December 31, 2019 $ 5,728    $ 22    $ 5,750   
Expenses incurred (a) 7,621    366    7,987   
Cash payments made (9,034)   (366)   (9,400)  
Balance as of March 31, 2020 $ 4,315    $ 22    $ 4,337   
(a) The amount of expenses incurred for the three months ended March 31, 2020 excludes $0.7 million of facility lease closure and lease termination costs that are reflected as a reduction of operating lease right-of-use assets on the unaudited condensed consolidated balance sheet under ASC 842.
The Company expects the employee severance costs accrued as of March 31, 2020 will be paid within the next twelve months. Certain facility costs will be paid over the remaining lease terms of the exited facilities that range from 2020 through 2027. Liabilities associated with these costs are included in accrued expenses and other long-term liabilities on the accompanying condensed consolidated balance sheets.
7. Shareholders' Equity
Shares Outstanding
Shares of common stock outstanding were as follows (in thousands):
Three Months Ended March 31,
2020 2019
Common stock shares, beginning balance 103,866    103,372   
   Repurchases of common stock (600)   (673)  
   Issuances of common stock 895    1,054   
Common stock shares, ending balance 104,161    103,753   
Stock Repurchase Program
On February 26, 2018, the Company’s Board of Directors (the "Board") authorized the repurchase of up to an aggregate of $250.0 million of the Company’s common stock to be executed from time to time in open market transactions effected through a broker at prevailing market prices, in block trades, or through privately negotiated transactions (the "stock repurchase program”). On December 5, 2019, the Board increased the dollar amount authorized under the stock repurchase program to up to an aggregate of $300.0 million and extended the term of the stock repurchase program to December 31, 2020. The Company intends to use cash on hand and future operating cash flow to fund the stock repurchase program.
The stock repurchase program does not obligate the Company to repurchase any particular amount of the Company’s common stock and may be modified, extended, suspended, or discontinued at any time. The timing and amount of repurchases will be determined by the Company’s management based on a variety of factors such as the market price of the Company’s common stock, the Company’s corporate requirements for cash, and overall market conditions. The stock repurchase program is subject to applicable legal requirements, including federal and state securities laws and applicable Nasdaq rules. The Company may also repurchase shares of its common stock pursuant to a trading plan meeting the requirements of Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, which would
17



permit shares of the Company’s common stock to be repurchased when the Company might otherwise be precluded from doing so by law.
The following table sets forth repurchase activity under the stock repurchase program from inception through March 31, 2020:
Total number of shares purchased Average price
paid per share 		Approximate dollar value of shares purchased (in thousands)
March 2018 948,100    $ 39.55    $ 37,493   
April 2018 1,024,400    36.60    37,492   
January 2019 552,100    39.16    21,623   
February 2019 120,600    41.40    4,993   
June 2019 509,100    45.29    23,055   
August 2019 141,100    49.93    7,045   
March 2020 600,000    53.38    32,029   
Total 3,895,400 $ 163,730   
The Company immediately retired all of the repurchased common stock and charged the par value of the shares to common stock. The excess of the repurchase price over the par value was applied on a pro rata basis against additional paid-in capital, with the remainder applied to accumulated deficit.
As of March 31, 2020, the Company had remaining authorization to repurchase up to approximately $136.3 million of shares of its common stock under the stock repurchase program.
8. Earnings (Loss) Per Share
The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings (loss) per share computations (in thousands, except per share data):
Three Months Ended March 31,
2020 2019
Numerator:
Net income (loss) $ 33,574    $ (30,004)  
Denominator:
Basic weighted average common shares outstanding 104,265    103,365   
Effect of dilutive securities:
Stock options and other awards under deferred share-based compensation programs 1,377    —   
Diluted weighted average common shares outstanding 105,642    103,365   
Earnings (loss) per share:
Basic $ 0.32    $ (0.29)  
Diluted $ 0.32    $ (0.29)  
Potential common shares outstanding that are considered anti-dilutive are excluded from the computation of diluted earnings (loss) per share. Potential common shares related to stock options and other awards under share-based compensation programs may be determined to be anti-dilutive based on the application of the treasury stock method. Potential common shares are also considered anti-dilutive in periods when the Company incurs a net loss.
18



The number of potential shares outstanding that were anti-dilutive and therefore excluded from the computation of diluted earnings (loss) per share, weighted for the portion of the period they were outstanding were as follows (in thousands):
Three Months Ended March 31,
2020 2019
Anti-dilutive stock options and other awards 911    294   
Anti-dilutive stock options and other awards under share-based compensation programs excluded based on reporting a net loss for the period —    1,438   
Total common stock equivalents excluded from diluted earnings (loss) per share 911    1,732   

9. Income Taxes
Income Tax Expense
For the three months ended March 31, 2020, the Company recorded income tax expense of $8.2 million, compared to pre-tax income of $41.8 million. Income tax expense for the three months ended March 31, 2020 included $7.1 million of discrete tax benefits primarily related to excess tax benefits from stock-based compensation and the benefit from foreign tax credits related to prior years that were quantified or claimed on amended returns during the period. The effective tax rate for the three months ended March 31, 2020, excluding discrete items, varied from the United States federal statutory income tax rate of 21.0% primarily due to foreign income inclusions such as the Global Intangible Low-Taxed Income provisions ("GILTI"), state and local taxes on United States income, and research and general business credits.
For the three months ended March 31, 2019, the Company recorded income tax expense of $10.4 million, compared to a pre-tax loss of $19.6 million. The effective tax rate for the three months ended March 31, 2019 varied from the United States federal statutory income tax rate of 21.0% primarily due to base erosion and anti-abuse minimum tax ("BEAT"), foreign income inclusions such as GILTI, and a valuation allowance change on domestic deferred tax assets. For the three months ended March 31, 2019, no material discrete tax expense or benefit existed.
BEAT
The Tax Cuts and Jobs Act of 2017 introduced a new tax on United States corporations that derive tax benefits from deductible payments to non-United States affiliates called BEAT. BEAT applies when base eroding payments are in excess of three percent of the Company’s total deductible payments and also where BEAT exceeds regular United States taxable income, similar to an alternate minimum tax. Changes to the Company’s contractual arrangements, operating structure, and/or final regulations that modify the application of this provision could have a material impact on the Company’s tax provision.
The Company does not anticipate its base eroding payments to exceed the three percent threshold of its deductible payments in 2020; therefore, the Company has not recorded any associated BEAT liability for the three months ended March 31, 2020.
Unrecognized Tax Benefits
The Company's gross unrecognized tax benefits, exclusive of associated interest and penalties, were $23.6 million and $23.2 million as of March 31, 2020 and December 31, 2019, respectively. The increase of $0.4 million was primarily due to an unrecognized tax benefit in the United States.
Tax Returns Under Audit
During the first quarter of 2019, the Company was notified by the Internal Revenue Service that the legacy inVentiv federal income tax return was under audit for the tax year beginning November 10, 2016
19



and ending December 31, 2016. The examination commenced on May 8, 2019. Additionally, income tax returns are currently under examination by tax authorities in several state and foreign jurisdictions. Management regularly assesses the potential outcomes of both ongoing and potential future examinations and has concluded that the provisions for income taxes adequately reflects their impact.
New Tax Legislation
Many governments have enacted or are currently contemplating economic stimulus and financial aid measures. Many of these measures include deferring the due dates for tax payments, including both income tax and other taxes. The Coronavirus Aid, Relief, and Economic Security Act ("CARES Act") was enacted on March 27, 2020 in the United States to address the economic impacts of the COVID-19 pandemic. The CARES Act includes corporate income tax, payroll tax, and other provisions. While the Company may receive financial, tax, or other benefits under the bill, this legislation did not impact the Company during the three months ended March 31, 2020. The Company is still assessing the impact of the CARES Act and other global measures and does not expect there to be a material impact to its income tax provision for the year ending December 31, 2020. The Company plans to defer the timing of income tax payments and other taxes as permitted by the CARES Act, and other stimulus measures enacted globally.
10. Revenue from Contracts with Customers
Unsatisfied Performance Obligations
As of March 31, 2020, the total aggregate transaction price allocated to the unsatisfied performance obligations under contracts with contract terms greater than one year and that are not accounted for as a series pursuant to ASU No. 2014-09, Revenue from Contracts with Customers (“ASC 606”) was $5.25 billion. This amount includes revenue associated with reimbursable out-of-pocket expenses. The Company expects to recognize revenue over the remaining contract term of the individual projects, with contract terms generally ranging from one to five years. The amount of unsatisfied performance obligations is presented net of any constraints and as a result, is lower than the potential contractual revenue. The contracts excluded due to constraints include contracts that do not commence within a certain period of time or that require the Company to undertake numerous activities to fulfill these performance obligations, including various activities that are outside of the Company’s control. Accordingly, such contracts have been excluded from the unsatisfied performance obligations balance presented above.
Timing of Billing and Performance
During the three months ended March 31, 2020, the Company recognized approximately $328.9 million of revenue that was included in the deferred revenue balance at the beginning of the period. During the three months ended March 31, 2020, approximately $3.2 million of the Company’s revenue recognized was allocated to performance obligations partially satisfied in previous periods and predominately related to changes in scope and estimates in full service clinical studies. Changes in unbilled services (including contract assets) and deferred revenue balances during the three months ended March 31, 2020 were not materially impacted by any other factors.
11. Segment Information
The Company is managed through two reportable segments: Clinical Solutions and Commercial Solutions. Each reportable segment consists of multiple service offerings that, when combined, create a fully integrated biopharmaceutical services organization. Clinical Solutions offers a variety of services spanning Phase I to Phase IV of clinical development, including full-service global studies, as well as individual service offerings such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process. Commercial Solutions provides the pharmaceutical, biotechnology, and healthcare industries with commercialization services, including deployment solutions, communication solutions (public relations and advertising), and consulting services. 
20



The Company’s Chief Operating Decision Maker (“CODM”) reviews segment performance and allocates resources based upon segment revenue and income from operations. Inter-segment revenue is eliminated from the segment reporting presented to the CODM and is not included in the segment revenue presented in the table below. Certain costs are not allocated to the Company’s reportable segments and are reported as general corporate expenses. These costs primarily consist of share-based compensation and general operating expenses associated with the Board and the Company’s senior leadership, finance, investor relations, and internal audit functions. The Company does not allocate depreciation, amortization, asset impairment charges, restructuring and other costs, or transaction and integration-related expenses to its segments. Additionally, the CODM reviews the Company’s assets on a consolidated basis and does not allocate assets to its reportable segments for purposes of assessing segment performance or allocating resources.
Information about reportable segment operating results was as follows (in thousands):
Three Months Ended March 31,
2020 2019
Revenue:
Clinical Solutions $ 874,826    $ 804,958   
Commercial Solutions 288,529    314,048   
Total revenue 1,163,355    1,119,006   
Segment direct costs:
Clinical Solutions 677,091    625,767   
Commercial Solutions 238,741    252,873   
Total segment direct costs 915,832    878,640   
Segment selling, general, and administrative expenses:
Clinical Solutions 74,559    69,702   
Commercial Solutions 24,395    26,053   
Total segment selling, general, and administrative expenses 98,954    95,755   
Segment operating income:
Clinical Solutions 123,176    109,489   
Commercial Solutions 25,393    35,122   
Total segment operating income 148,569    144,611   
Direct costs and operating expenses not allocated to segments:
Share-based compensation included in direct costs 8,182    8,162   
Share-based compensation included in selling, general, and administrative expenses 7,816    6,105   
Corporate selling, general, and administrative expenses 11,200    11,257   
Restructuring and other costs 8,720    14,413   
Transaction and integration-related expenses 7,577    16,658   
Depreciation and amortization 56,107    61,200   
Total income from operations $ 48,967    $ 26,816   

21



12. Operations by Geographic Location
The following table summarizes total revenue by geographic area (in thousands, all intercompany transactions have been eliminated):
Three Months Ended March 31,
2020 2019
Revenue:
North America (a) $ 753,045    $ 727,698   
Europe, Middle East, and Africa 268,022    258,347   
Asia-Pacific 117,053    111,566   
Latin America 25,235    21,395   
Total revenue $ 1,163,355    $ 1,119,006   
(a) Revenue for the North America region includes revenue attributable to the United States of $713.4 million and $704.1 million, or 61.3% and 62.9% of total revenue, for the three months ended March 31, 2020 and 2019, respectively. No other countries represented more than 10% of total revenue for any period.
The following table summarizes long-lived assets by geographic area (in thousands, all intercompany transactions have been eliminated):
March 31, 2020 December 31, 2019
Property and equipment, net:    
North America (a) $ 153,914    $ 159,709   
Europe, Middle East, and Africa 27,454    28,514   
Asia-Pacific 11,554    12,742   
Latin America 2,698    2,961   
  Total property and equipment, net $ 195,620    $ 203,926   
(a) Long-lived assets for the North America region include property and equipment, net attributable to the United States of $148.0 million and $153.1 million as of March 31, 2020 and December 31, 2019, respectively.
13. Concentration of Credit Risk
Financial assets that subject the Company to credit risk primarily consist of cash and cash equivalents, accounts receivable and unbilled services (including contract assets). The Company's cash and cash equivalents consist principally of cash and are maintained at several financial institutions with reputable credit ratings. The Company maintains cash depository accounts with several financial institutions worldwide and is exposed to credit risk related to the potential inability to access liquidity in financial institutions where its cash and cash equivalents are concentrated. The Company has not historically incurred any losses with respect to these balances and believes that they bear minimal credit risk.
As of March 31, 2020 and December 31, 2019, substantially all of the Company’s cash and cash equivalents were held within the United States.
No single customer accounted for greater than 10% of the Company’s revenue for the three months ended March 31, 2020 and 2019.

As of March 31, 2020 and December 31, 2019, no single customer accounted for greater than 10% of the Company’s accounts receivable and unbilled services (including contract assets) balances.
22



14. Related-Party Transactions
There were no material related party transactions for the three months ended March 31, 2020.
For the three months ended March 31, 2019, the Company incurred reimbursable out-of-pocket expenses of $1.1 million for professional services obtained from a provider whose board of directors included a member who was also a member of the Company's Board. Additionally, as of March 31, 2019, the Company had liabilities of $0.8 million included in accounts payable and accrued expenses on the condensed consolidated balance sheets associated with this related party. This provider ceased to be a related-party as of December 31, 2019. No material related-party revenue was recorded for the three months ended March 31, 2019.
15. Commitments and Contingencies
Legal Proceedings
The Company is party to legal proceedings incidental to its business. While the Company's management currently believes the ultimate outcome of these proceedings, individually and in the aggregate, will not have a material adverse effect on the Company's consolidated financial statements, litigation is subject to inherent uncertainties. Were an unfavorable ruling to occur, there exists the possibility of a material adverse impact on the Company's financial condition and results of operations.
On December 1, 2017, the first of two virtually identical actions alleging federal securities law claims was filed against the Company and certain of its officers on behalf of a putative class of its shareholders. The first action, captioned Bermudez v. INC Research, Inc., et al, No. 17-09457 (S.D.N.Y.) in the Southern District of New York, names as defendants the Company, Michael Bell, Alistair MacDonald, Michael Gilbertini, and Gregory S. Rush (the "Bermudez action"), and the second action, Vaitkuvienë v. Syneos Health, Inc., et al, No. 18-0029 (E.D.N.C.) in the Eastern District of North Carolina, filed on January 25, 2018 (the "Vaitkuvienë action"), names as defendants the Company, Alistair MacDonald, and Gregory S. Rush (the "Initial Defendants"). Both complaints allege similar claims under Section 10(b) and Section 20(a) of the Securities Exchange Act of 1934 on behalf of a putative class of purchasers of the Company's common stock between May 10, 2017 and November 8, 2017 and November 9, 2017. The complaints allege that the Company published inaccurate or incomplete information regarding, among other things, the financial performance and business outlook for inVentiv’s business prior to the Merger and with respect to the combined company following the Merger. On January 30, 2018, two alleged shareholders separately filed motions seeking to be appointed lead plaintiff and approving the selection of lead counsel. On March 30, 2018, Plaintiff Bermudez filed a notice of voluntary dismissal of the Bermudez action, without prejudice, and as to all defendants. On May 29, 2018, the Court in the Vaitkuvienë action appointed the San Antonio Fire & Police Pension Fund and El Paso Firemen & Policemen’s Pension Fund as Lead Plaintiffs and, on June 7, 2018, the Court entered a schedule providing for, among other things, Lead Plaintiffs to file an amended complaint by July 23, 2018 (later extended to July 30, 2018). Lead Plaintiffs filed their amended complaint on July 30, 2018, which also includes a claim against the Initial Defendants, as well as each member of the board of directors at the time of the INC Research - inVentiv Health merger vote in July 2017 (the “Defendants”), contending that the inVentiv merger proxy was misleading under Section 14(a) of the Act. Lead Plaintiffs seek, among other things, orders (i) declaring that the lawsuit is a proper class action and (ii) awarding compensatory damages in an amount to be proven at trial, including interest thereon, and reasonable costs and expenses incurred in this action, including attorneys’ fees and expert fees, to Lead Plaintiffs and other class members. Defendants filed a Motion to Dismiss Plaintiffs’ Amended Complaint on September 20, 2018. Lead Plaintiffs filed a Response in Opposition to such motion on November 21, 2018, and Defendants filed a Reply to such response on December 5, 2018. On May 23, 2019, Lead Plaintiffs filed a Notice of Filings in Related Case regarding the New Jersey shareholder action filed on March 1, 2019 described below, pending before the United States District Court for the District of New Jersey (the “New Jersey Action”), and Defendants filed their response on May 31, 2019. On September 26, 2019, the Court ordered, among other things, that this action is stayed in light of the New Jersey Action. On March 23, 2020, Defendants filed a Notice of Disposition of a Related Action, notifying the Court that the New Jersey Action was dismissed and requesting that the stay in this action should be lifted. The Company and the other defendants deny the
23



allegations in these complaints and intend to defend vigorously against these claims.
On March 1, 2019, a complaint was filed in the United States District Court for the District of New Jersey on behalf of a putative class of shareholders who purchased the Company's common stock during the period between May 10, 2017 and February 27, 2019. The action, captioned Murakami v. Syneos Health, Inc. et al, No. 19-7377 (D.N.J.), named the Company and certain of its executive officers as defendants and alleged violations of the Securities Exchange Act of 1934, as amended, based on allegedly false or misleading statements about its business, operations, and prospects. The plaintiffs sought awards of compensatory damages, among other relief, and their costs and attorneys’ and experts’ fees. On March 28, 2019, Lead Plaintiffs in the Vaitkuvienë action filed a motion to intervene and to transfer this action to the Eastern District of North Carolina, and the Company filed its response on April 22, 2019. On April 30, 2019, a shareholder filed a motion seeking to be appointed lead plaintiff and approving the selection of lead counsel. On October 16, 2019, the Court ordered that Plaintiff, by November 8, 2019, file proof of service of the Complaint in Compliance with Rule 4, or otherwise show cause why the action should not be dismissed for failure to properly serve Defendants (the "Order to Show Cause"). The Court further ordered that the action is stayed and that both motions are administratively terminated pending the Court's resolution of the Order to Show Cause. Plaintiff filed a response to the Order to Show Cause on November 8, 2019, and the Company and the other defendants filed a response on November 20, 2019. On March 20, 2020, the Court dismissed this action without prejudice for failure to serve defendants within the time period required by law.
The Company is presently unable to predict the duration, scope, or result of the Vaitkuvienë action, or any other related lawsuit. As such, the Company is presently unable to develop a reasonable estimate of a possible loss or range of losses, if any, related to this matter. While the Company intends to defend the putative class action litigation vigorously, the outcome of such litigation or any other litigation is necessarily uncertain. The Company could be forced to expend significant resources in the defense of this lawsuit or future ones, and it may not prevail. As such, these matters could have a material adverse effect on the Company's business, annual, or interim results of operations, cash flows, or its financial condition.
Assumed Contingent Tax-Sharing Obligations
As a result of the Merger, the Company assumed contingent tax-sharing obligations arising from inVentiv Health, Inc.'s 2016 merger with Double Eagle Parent, Inc. As of March 31, 2020 and December 31, 2019, the estimated fair value of the assumed contingent tax-sharing obligations was $6.4 million and $32.7 million, respectively.
Contingent Earn-out Liability
In connection with the acquisition of Kinapse Topco Limited ("Kinapse") in August 2018, the Company recorded a contingent earn-out liability to be paid based on Kinapse meeting revenue targets as of March 31, 2021. The estimated fair value of the contingent earn-out liability was $4.6 million as of December 31, 2019 and was included in other long-term liabilities in the condensed consolidated balance sheet. During the three months ended March 31, 2020, the Company adjusted the fair value of the contingent earn-out liability to zero to reflect the updated probability of achievement of the revenue targets. The change in fair value of the earn-out liability was recorded in transaction and integration-related expenses in the condensed consolidated statement of operations.
24



Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Forward Looking Statements
You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q, and with our audited consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019.
In addition to historical condensed consolidated financial information, this Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect, among other things, our current expectations and anticipated results of operations, all of which are subject to known and unknown risks, uncertainties, and other factors that may cause our actual results, performance or achievements, market trends, or industry results to differ materially from those expressed or implied by such forward-looking statements. Therefore, any statements contained herein that are not statements of historical fact may be forward-looking statements and should be evaluated as such, including statements regarding our anticipated results of operations, our business strategy, possible impairment charges, the anticipated impact of the COVID-19 pandemic on our business, financial results, and financial condition, and planned capital expenditures. Without limiting the foregoing, the words “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “might,” “plans,” “projects,” “should,” “would,” “targets,” “will” and the negative thereof, and similar words and expressions are intended to identify forward-looking statements. Unless legally required, we assume no obligation to update any such forward-looking information to reflect actual results or changes in the factors affecting such forward-looking information.
We caution you that any such forward-looking statements are further qualified by important factors that could cause our actual operating results to differ materially from those in the forward-looking statements, including without limitation, regional, national, or global political, economic, business, competitive, market, and regulatory conditions and the following: the need to hire, develop, and retain key personnel; the impact of unfavorable economic conditions, including the uncertain international economic environment, changes in exchange rates, and effective income tax rate fluctuations; the impact of potentially underpricing our contracts, overrunning our cost estimates, or failing to receive approval for or experiencing delays with documentation of change orders; any adverse effects from customer or therapeutic area concentration; our potential failure to generate a large number of new business awards and the risk of delay, termination, reduction in scope, or failure to go to contract of our business awards; our potential failure to convert backlog to revenue; fluctuations in our operating results and effective income tax rate; risks associated with the COVID-19 pandemic; the cyber-security and other risks associated with our information systems infrastructure; risks associated with the integration of our business with the business of Double Eagle Parent, Inc. (“inVentiv”) and our operation of the combined business following the closing of the merger with inVentiv (the “Merger”); the risks associated with doing business internationally; risks related to the impact of the U.K.’s withdrawal from the European Union; impact of the Tax Cuts and Jobs Act; challenges by tax authorities of our intercompany transfer pricing policies; our potential failure to successfully increase our market share, grow our business, and execute our growth strategies; our ability to effectively upgrade our information systems; our failure to perform our services in accordance with contractual requirements, regulatory standards, and ethical considerations; the risk of litigation and personal injury claims; risks related to the management of clinical trials; failure of our insurance to cover our indemnification obligations and other liabilities; risks related to marketing drugs for biopharmaceutical companies; our ability to protect our intellectual property; the risks associated with potential future acquisitions or investments in our customers’ businesses or drugs; our relationships with customers who are in competition with each other; any failure to realize the full value of our goodwill and intangible assets; risks related to restructuring; our compliance with anti-corruption and anti-bribery laws; our dependence on third parties; potential employment liability; downgrades of our credit ratings; outsourcing trends and changes in aggregate spending and research and development budgets; the impact of, including changes in, government regulations and healthcare reform; our ability to keep pace with rapid technological change; the cost of and our ability to service our substantial indebtedness; and
25


Table of Contents

other risks related to ownership of our common stock. For a further discussion of the risks relating to our business, refer to “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2019.
Overview of Our Business and Services
Syneos Health, Inc. (the “Company,” “we,” “us,” and “our”) is a leading global biopharmaceutical solutions organization providing a full suite of clinical and commercial services to customers in the biopharmaceutical, biotechnology, and medical device industries. We offer both stand-alone and integrated biopharmaceutical product development solutions through our Contract Research Organization (“CRO”) and Contract Commercial Organization (“CCO”), ranging from Early Phase (Phase I) clinical trials to the full commercialization of biopharmaceutical products, with the goal of increasing the likelihood of regulatory approval and commercial success.
Our operations are divided into two reportable segments, Clinical Solutions and Commercial Solutions, to reflect the structure under which we operate, evaluate our performance, make strategic decisions, and allocate resources. Our Clinical Solutions segment offers a variety of services spanning Phase I-IV of clinical development, including full-service global studies, as well as individual service offerings such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process. Our Commercial Solutions segment provides the pharmaceutical, biotechnology, and healthcare industries with commercialization services, including deployment solutions, communication solutions (public relations and advertising), and consulting services. We integrate our clinical and commercial capabilities into customized solutions by sharing knowledge, data, and insights through our biopharmaceutical acceleration model (“BAM”). This collaboration across the development and commercialization continuum facilitates unique insights into patient populations, therapeutic environments, product timelines, and the competitive landscape. For further discussion, refer to “Note 11 - Segment Information” of our unaudited condensed consolidated financial statements in Part I, Item 1 of this Quarterly Report on Form 10-Q.
COVID-19 Pandemic
On March 11, 2020, the World Health Organization designated the outbreak of the novel strain of coronavirus known as COVID-19 as a global pandemic. Governments and businesses around the world have taken unprecedented actions to mitigate the spread of COVID-19, including, but not limited to, shelter-in-place orders, quarantines, significant restrictions on travel, as well as restrictions that prohibit many employees from going to work. Uncertainty with respect to the economic effects of the pandemic has introduced significant volatility in the financial markets.
During the first quarter of 2020, we implemented contingency planning to protect the health and well-being of our employees, with most employees working remotely where possible. We have global and regional crisis teams in place monitoring the rapidly evolving situation and recommending risk mitigation actions. We have implemented travel restrictions as well as visitor protocols and we are following social distancing practices. We have assessed and are implementing continuity plans to provide customers with continued services.
We did not observe significant impacts on our business or results of operations for the quarter ended March 31, 2020 due to the global emergence of COVID-19 or the mitigation actions taken to slow its spread. We maintained new business award growth in both of our segments, and did not experience any significant cancellations related to COVID-19.
During and since March 2020, the COVID-19 pandemic and its adverse effects have become more prevalent in the locations where we, our customers, suppliers, and partners conduct significant portions of our business, such as Europe and North America, and, as a result, we expect to begin to experience more pronounced disruptions in our operations during the second quarter of 2020. We have experienced, and may continue to experience, curtailed customer demand that could materially adversely impact our business, results of operations, and overall financial performance in future periods. As a result of these conditions, we are taking proactive steps to mitigate the projected revenue and cash flow impacts for the
26


Table of Contents

remainder of 2020, including proactive cost management strategies consisting of accelerating our ForwardBound margin enhancement initiative, hiring restrictions, reductions in third-party costs, certain compensation adjustments, and other initiatives.
Specifically, in our Clinical Solutions segment, we expect impacts to be temporary and relate to limitations on our staff's ability to physically access investigative sites, delays in new patient enrollment, delays in new trial start-up activities, and delayed decision making related to new business awards. Our full service studies as well as our functional service provider offering are also expected to be impacted by a switch from site-based monitoring visits to remote monitoring visits and temporary or permanent closures of businesses that utilize our services or facilities we use to conduct our business during the pandemic. In our Commercial Solutions segment, we expect impacts to be temporary and relate to delayed decision making related to new business awards, delays of existing projects, declines in field sales team visits to healthcare providers, and travel disruptions.
We remain confident in our liquidity position, which includes cash on hand of $336.0 million as of March 31, 2020, and access to our revolving credit facility, of which we drew $300.0 million during March 2020. We have also implemented proactive cash conservation initiatives, including delaying certain capital expenditures, reducing operating costs, and purchasing interest rate swaps to fix certain variable rate debt at lower interest rates.
To the extent that COVID-19 continues or worsens, national, state, and local governments may impose additional restrictions or extend the restrictions already in place. The continuing spread of COVID-19 and the related safety and business operating restrictions could result in a number of adverse impacts to our business, including, but not limited to, additional disruption to the economy and our customers, additional work restrictions, and supply chains being interrupted or slowed. Also, governments may impose other laws, regulations, or taxes that could adversely impact our business, financial condition, or results of operations. Further, depending on the extent to which our customers are affected, they could delay or reduce purchases of services we provide. The potential effects of COVID-19 also could impact us in a number of other ways including, but not limited to, reductions to our profitability, fluctuations in foreign currency markets, the availability of future borrowings, the cost of borrowings, credit risks of our customers and counterparties, and potential impairment of the carrying amount of goodwill or other definite-lived assets.
We will continue to actively monitor the situation and may take further precautionary and preemptive actions as may be required by national, state, or local authorities or that we determine are in the best interests of our employees, customers, partners, suppliers, and shareholders. To the extent the pandemic worsens, we cannot predict the effects it may have on our business, in particular with respect to demand for our services, our strategy, and our prospects, the effects on our customers, or the impact on our financial results. See Part II, Item 1A "Risk Factors" of this Quarterly Report on Form 10-Q for further discussion of the potential impact of the COVID-19 pandemic on our business.
New Business Awards and Backlog
We add new business awards to backlog when we enter into a contract or when we receive a written commitment from the customer selecting us as a service provider, provided that:
•the customer has received appropriate internal funding approval and collection of the award value is probable;
•the project or projects are not contingent upon completion of another clinical trial or event that would place the project or projects at material risk of not commencing in accordance with the expected timeline;
•the project or projects are expected to commence within a certain period of time from the end of the quarter in which the award was granted;
27


Table of Contents

•the customer has entered or intends to enter into a comprehensive contract as soon as practicable; and
•for awards related to deployment solutions and functional service provider offerings, a maximum of twelve months of services are included in the award value.
In addition, we continually evaluate our backlog to determine if any of the previously awarded work is no longer expected to be performed, regardless of whether we have received formal cancellation notice from the customer. If we determine that any previously awarded work is no longer probable of being performed, we remove the value from our backlog based on the risk of cancellation. We recognize revenue from these awards as services are performed, provided we have entered into a contract with the customer.
We report new business awards for our Clinical Solutions and Commercial Solutions segments on a trailing twelve months (“TTM”) basis. Our total backlog represents backlog for our Clinical Solutions segment and the deployment solutions offering within our Commercial Solutions segment. We do not report backlog for the remaining service offerings in the Commercial Solutions segment.
Backlog
Our backlog consists of anticipated future revenue from business awards that either have not started, or that are in process and have not been completed. Our backlog also reflects any cancellation or adjustment activity related to these awards. The average duration of our contracts will fluctuate from period to period based on the contracts comprising our backlog at any given time. The majority of our contracts can be terminated by the customer with a 30-day notice.
Our backlog was as follows as of March 31 (in millions):
2020 2019 Change
Clinical Solutions $ 8,549.4    $ 7,612.9    $ 936.5    12.3  %
Commercial Solutions - Deployment Solutions 658.1    690.2    (32.1)   (4.7) %
Total backlog $ 9,207.5    $ 8,303.1    $ 904.4    10.9  %
We expect approximately $3.06 billion of our backlog as of March 31, 2020 will be recognized as revenue during the remainder of 2020. We adjust the amount of our backlog each quarter for the effects of fluctuations in foreign currency exchange rates.
Net New Business Awards
New business awards, net of cancellations, were as follows for the TTM periods ended March 31 (in millions):
2020 2019
Clinical Solutions $ 4,451.3    $ 4,193.5   
Commercial Solutions 1,273.4    1,324.6   
    Total net new business awards $ 5,724.7    $ 5,518.1   
New business awards have varied and may continue to vary significantly from quarter to quarter. Fluctuations in our net new business award levels often result from the fact that we may receive a small number of relatively large orders in any given reporting period. Because of these large orders, our backlog and net new business awards in a reporting period may reach levels that are not sustainable in subsequent reporting periods.
We believe that our backlog and net new business awards might not be consistent indicators of future revenue because they have been, and likely will continue to be, affected by a number of factors, including the variable size and duration of projects, many of which are performed over several years, and changes to the scope of work during the course of projects. Additionally, projects may be canceled or delayed by
28


Table of Contents

the customer or regulatory authorities. Net new business awards and backlog could also be affected by various risks and uncertainties, including, but not limited to, the broad effects of the COVID-19 pandemic on the global economy and major financial markets, as well as other risks detailed in Part II, Item 1A "Risk Factors" of this Quarterly Report on Form 10-Q. We generally do not have a contractual right to the full amount of the awards reflected in our backlog. If a customer cancels an award, we might be reimbursed for the costs we have incurred. As we increasingly compete for and enter into large contracts that are more global in nature, we expect that the rate at which our backlog and net new business awards convert into revenue is likely to decrease, and the duration of projects and the period over which related revenue is recognized to lengthen. For more information about risks related to our backlog see Part I, Item 1A "Risk Factors - Risks Related to Our Business - Our backlog might not be indicative of our future revenues, and we might not realize all of the anticipated future revenue reflected in our backlog" included in “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019.
Results of Operations
The following table sets forth amounts from our unaudited condensed consolidated statements of operations along with dollar and percentage changes (in thousands, except percentages):
Three Months Ended 
March 31,
2020 2019 Change
Revenue $ 1,163,355    $ 1,119,006    $ 44,349    4.0  %
Costs and operating expenses:                    
Direct costs (exclusive of depreciation and amortization) 924,014    886,802    37,212    4.2  %
Selling, general, and administrative expenses 117,970    113,117    4,853    4.3  %
Restructuring and other costs 8,720    14,413    (5,693)   (39.5) %
Transaction and integration-related expenses 7,577    16,658    (9,081)   (54.5) %
Depreciation and amortization 56,107    61,200    (5,093)   (8.3) %
Total operating expenses 1,114,388    1,092,190    22,198    2.0  %
Income from operations 48,967    26,816    22,151    82.6  %
Total other expense, net 7,192    46,404    (39,212)   84.5  %
Income (loss) before provision for income taxes 41,775    (19,588)   61,363    n/m   
Income tax expense 8,201    10,416    (2,215)   21.3  %
Net income (loss) $ 33,574    $ (30,004)   $ 63,578    n/m   
Revenue
For the three months ended March 31, 2020, our revenue increased by $0.04 billion, or 4.0%, to $1.16 billion from $1.12 billion for the three months ended March 31, 2019. The increase was primarily driven by growth in our Clinical Solutions segment, which was partially offset by a decrease in our Commercial Solutions segment as discussed below.
No single customer accounted for greater than 10% of our revenue for the three months ended March 31, 2020 and 2019. Revenue from our top five customers accounted for approximately 21% and 22% of revenue for the three months ended March 31, 2020 and 2019, respectively.




29


Table of Contents

Revenue for each of our segments was as follows (dollars in thousands):
Three Months Ended March 31,
2020 % of total 2019 % of total Change
Clinical Solutions $ 874,826    75.2  % $ 804,958    71.9  % $ 69,868    8.7  %
Commercial Solutions 288,529    24.8  % 314,048    28.1  % (25,519)   (8.1) %
Total revenue $ 1,163,355    $ 1,119,006    $ 44,349    4.0  %
Clinical Solutions
For the three months ended March 31, 2020, revenue attributable to our Clinical Solutions segment increased compared to the same period in the prior year primarily due to net new business awards resulting in higher backlog as we entered the period and growth in reimbursable out-of-pocket expenses, partially offset by the negative impacts of fluctuations in foreign currency exchange rates of $6.0 million.
Although we are aggressively managing our response to the COVID-19 pandemic, it is expected to negatively impact our full year 2020 Clinical Solutions revenue. At this time, we believe that the most significant impacts to revenue in our Clinical Solutions segment will be temporary and relate to limitations on our staff's ability to physically access investigative sites, delays in new patient enrollment, delays in new trial start-up activities, and delayed decision making related to new business awards. Our full service studies as well as our functional service provider offering are also expected to be impacted by a switch from site-based monitoring visits to remote monitoring visits and temporary or permanent closures of businesses that utilize our services or facilities we use to conduct our business during the pandemic.
Commercial Solutions
For the three months ended March 31, 2020, revenue attributable to our Commercial Solutions segment decreased compared to the same period in the prior year primarily due to unfavorable revenue mix and a decline in reimbursable out-of-pocket expenses.
Although we are aggressively managing our response to the COVID-19 pandemic, it is expected to negatively impact our full year 2020 Commercial Solutions revenue. At this time, we believe that the most significant impacts to revenue in our Commercial Solutions segment will be temporary and relate to delayed decision making related to new business awards, delays of existing projects, declines in field sales team visits to healthcare providers, and travel disruptions.
Direct Costs
Direct costs consist principally of compensation expense and benefits associated with our employees and other employee-related costs, and reimbursable out-of-pocket expenses directly related to delivering on our projects. While we have some ability to manage the majority of these costs relative to the amount of contracted services we have during any given period, direct costs as a percentage of revenue can vary from period to period. Such fluctuations are due to a variety of factors, including, among others: (i) the level of staff utilization on our projects; (ii) adjustments to the timing of work on specific customer contracts; (iii) the experience mix of personnel assigned to projects; (iv) the service mix and pricing of our contracts; and (v) the timing of the incurrence of reimbursable out-of-pocket expenses, particularly on our Clinical Solutions projects. In addition, as global projects wind down or as delays and cancellations occur, staffing levels in certain countries or functional areas can become misaligned with the current business volume.



30


Table of Contents

Direct costs consisted of the following (dollars in thousands):
Three Months Ended March 31,
2020 2019 Change
Direct costs (exclusive of depreciation and amortization) $ 924,014    $ 886,802    $ 37,212    4.2  %
% of revenue 79.4  % 79.2  %
Gross margin % 20.6  % 20.8  %
For the three months ended March 31, 2020, our direct costs increased by $37.2 million, or 4.2%, compared to the three months ended March 31, 2019. The increase was primarily driven by growth in our Clinical Solutions segment, partially offset by a decrease in our Commercial Solutions segment as discussed below.
Clinical Solutions
Direct costs for our Clinical Solutions segment, excluding share-based compensation expense, were as follows (dollars in thousands):
Three Months Ended March 31,
2020 2019 Change
Direct costs $ 677,091    $ 625,767    $ 51,324    8.2  %
% of segment revenue 77.4  % 77.7  %
Segment gross margin % 22.6  % 22.3  %
For the three months ended March 31, 2020, our Clinical Solutions segment direct costs increased by $51.3 million, or 8.2%, compared to the three months ended March 31, 2019. The increase was primarily due to higher reimbursable out-of-pocket expenses and an increase in compensation and related costs due to higher billable headcount to support revenue growth. These increases were partially offset by favorable impacts from our ForwardBound margin enhancement initiative and foreign currency exchange rate fluctuations.
Gross margin for our Clinical Solutions segment was 22.6% for the three months ended March 31, 2020, compared to 22.3% for the three months ended March 31, 2019. Gross margin was higher during the current year period as compared to the same period in 2019 primarily due to favorable revenue mix and impacts from our ForwardBound margin enhancement initiative, partially offset by higher reimbursable out-of-pocket expenses.
Although we are aggressively managing our response to the COVID-19 pandemic, it is expected to negatively impact our full year 2020 Clinical Solutions margins. At this time, we believe that the most significant impacts to margins in our Clinical Solutions segment will be those noted in the above Revenue section as well as potential increased costs related to inefficiencies, partially offset by proactive cost management strategies.
Commercial Solutions
Direct costs for our Commercial Solutions segment, excluding share-based compensation expense, were as follows (dollars in thousands):
Three Months Ended March 31,
2020 2019 Change
Direct costs $ 238,741    $ 252,873    $ (14,132)   (5.6) %
% of segment revenue 82.7  % 80.5  %
Segment gross margin % 17.3  % 19.5  %
31


Table of Contents

For the three months ended March 31, 2020, our Commercial Solutions segment direct costs decreased by $14.1 million, or 5.6%, compared to the three months ended March 31, 2019. The decrease was primarily related to a decline in reimbursable out-of-pocket expenses, lower compensation and related costs due to reduced billable headcount, and favorable impacts from our ForwardBound margin enhancement initiative.
Gross margin for our Commercial Solutions segment was 17.3% for the three months ended March 31, 2020, compared to 19.5% for the three months ended March 31, 2019. Gross margin was lower during the current year period compared to the same period in 2019 primarily due to an unfavorable revenue mix. This decrease was partially offset by lower reimbursable out-of-pocket expenses and favorable impacts from our ForwardBound margin enhancement initiative.
Although we are aggressively managing our response to the COVID-19 pandemic, it is expected to negatively impact our full year 2020 Commercial Solutions margins. At this time, we believe that the most significant impacts to margins in our Commercial Solutions segment will be those noted in the above Revenue section as well as potential increased costs related to inefficiencies, partially offset by proactive cost management strategies.
Selling, General, and Administrative Expenses
Selling, general, and administrative expenses were as follows (dollars in thousands):
Three Months Ended March 31,
2020 2019 Change
Selling, general, and administrative expenses $ 117,970    $ 113,117    $ 4,853    4.3  %
% of total revenue 10.1  % 10.1  %
The increase in selling, general, and administrative expenses for the three months ended March 31, 2020 as compared to the same period in 2019 was primarily caused by higher compensation and related costs primarily due to strategic investments in some of our key functions including business development, our Syneos OneTM product offering, and information technology. These increases were partially offset by favorable impacts from our ForwardBound margin enhancement initiative.
Restructuring and Other Costs
Restructuring and other costs were $8.7 million and $14.4 million for the three months ended March 31, 2020 and 2019, respectively. In connection with the Merger, we established a restructuring plan to eliminate redundant positions and reduce our facility footprint worldwide. We expect to continue the ongoing evaluations of our workforce and facilities infrastructure needs in an effort to optimize our resources. Additionally, for the three months ended March 31, 2020 and 2019, we incurred employee severance costs and facility closure costs for non Merger-related related restructuring activities.
Restructuring and other costs consisted of the following (in thousands):
Three Months Ended March 31,
2020 2019
Merger-related restructuring and other costs:
Employee severance and benefit costs $ 962    $ 6,272   
Facility and lease termination costs 597    1,954   
Non Merger-related restructuring and other costs:
Employee severance and benefit costs 6,659    5,960   
Facility and lease termination costs 136    219   
Other costs 366    8   
Total restructuring and other costs $ 8,720    $ 14,413   
32


Table of Contents

We expect to continue to incur significant costs related to the restructuring of our operations. However, the timing and the amount of these costs depends on various factors, including, but not limited to, identifying and realizing synergy opportunities and executing the integration of our combined operations. We may also incur additional restructuring and other costs during 2020 related to our cost savings initiatives, including our response to the COVID-19 pandemic and our ForwardBound margin enhancement initiative.
Transaction and Integration-Related Expenses
Transaction and integration-related expenses consisted of the following (in thousands):
Three Months Ended March 31,
2020 2019
Professional fees $ 10,123    $ 12,846   
Debt modification and related expenses —    2,241   
Integration and personnel retention-related costs 1,549    847   
Fair value adjustments to contingent obligations (4,095)   724   
Total transaction and integration-related expenses $ 7,577    $ 16,658   
We expect to incur additional professional fees and integration-related costs associated with the Merger and continued consolidation of our legal entities and information technology systems. The timing and amount of these expenses will depend on the identification of synergy opportunities and the timing and execution of our integration activities.
The decrease in fair value adjustments to contingent obligations during the three months ended March 31, 2020 as compared to 2019 is primarily due to a decrease in the estimate of the contingent earn-out liability associated with our acquisition of Kinapse Topco Limited in 2018.
Depreciation and Amortization Expense
Total depreciation and amortization expense was $56.1 million and $61.2 million for the three months ended March 31, 2020 and 2019, respectively. The decrease in total depreciation and amortization expense was primarily due to a decrease in amortization expense from intangible assets resulting from business combinations completed in prior periods and a decrease in depreciation expense related to an increase in assets that are fully amortized.
Other Expense, Net
Other expense, net consisted of the following (dollars in thousands):
Three Months Ended March 31,
2020 2019 Change
Interest income $ (336)   $ (1,502)   $ 1,166    (77.6) %
Interest expense 26,458    34,630    (8,172)   23.6  %
Loss on extinguishment of debt —    4,355    (4,355)   100.0  %
Other (income) expense, net (18,930)   8,921    (27,851)   (312.2) %
Total other expense, net $ 7,192    $ 46,404    $ (39,212)   84.5  %
Total other expense, net was $7.2 million and $46.4 million for the three months ended March 31, 2020 and 2019, respectively. The change was primarily due to higher other (income) expense, net, and a decrease in interest expense in the current period as compared to the prior period. Other (income) expense, net primarily consists of foreign currency gains and losses that result from exchange rate fluctuations on our monetary asset balances denominated in currencies other than our functional currency.
33


Table of Contents

Income Tax Expense
For the three months ended March 31, 2020, we recorded income tax expense of $8.2 million, compared to pre-tax income of $41.8 million. The effective tax rate for the three months ended March 31, 2020 varied from the United States federal statutory income tax rate of 21.0% primarily due to foreign income inclusions such as the Global Intangible Low-Taxed Income provisions ("GILTI"), state and local taxes on United States income, and research and general business credits.
For the three months ended March 31, 2019, we recorded income tax expense of $10.4 million, compared to pre-tax loss of $19.6 million. The effective tax rate for the three months ended March 31, 2019 varied from the United States federal statutory income tax rate of 21.0% primarily due to base erosion and anti-abuse minimum tax, foreign income inclusions such as GILTI, and valuation allowance changes on domestic deferred tax assets.
We currently maintain a valuation allowance against a portion of our state deferred tax assets and a portion of our foreign deferred tax assets as of March 31, 2020. We intend to continue to maintain a valuation allowance on these deferred tax assets until there is sufficient evidence to support the reversal of all or some portion of these allowances.
Many governments have enacted or are currently contemplating economic stimulus and financial aid measures. Many of these measures include deferring the due dates for tax payments, including both income tax and other taxes. The Coronavirus Aid, Relief, and Economic Security Act ("CARES Act") was enacted on March 27, 2020 in the United States to address the economic impacts of the COVID-19 pandemic. The CARES Act includes corporate income tax, payroll tax, and other provisions. While we may receive financial, tax, or other benefits under the bill, this legislation did not impact us during the three months ended March 31, 2020. We are still assessing the impact of the CARES Act and other global measures and do not expect there to be a material impact to our income tax provision for the year ending December 31, 2020. We plan to defer the timing of income tax payments and other taxes as permitted by the CARES Act, and other stimulus measures enacted globally.
Liquidity and Capital Resources
Key measures of our liquidity were as follows (in thousands):
March 31, 2020 December 31, 2019
Balance sheet statistics:
Cash and cash equivalents $ 335,573    $ 163,227   
Restricted cash 387    462   
Working capital (excluding restricted cash) 333,141    45,241   
As of March 31, 2020, we had $336.0 million of cash, cash equivalents, and restricted cash, which reflects a $300.0 million draw on our $600.0 million revolving credit facility (the "Revolver") in March 2020. As of March 31, 2020, substantially all of our cash, cash equivalents, and restricted cash was held within the United States. In addition, we had $280.8 million (net of $19.2 million in outstanding letters of credit ("LOCs")) available for borrowing under our Revolver, of which $130.8 million was available for LOCs.
We have historically funded our operations and growth, including acquisitions, primarily with our working capital, cash flow from operations, and funds available through various borrowing arrangements. Our principal liquidity requirements are to fund our debt service obligations, capital expenditures, expansion of service offerings, possible acquisitions, integration and restructuring costs, geographic expansion, stock repurchases, working capital, and other general corporate expenses. Cash from operations also could be affected by various risks and uncertainties, including, but not limited to, the effects of the COVID-19 pandemic on the global economy and major financial markets, as well as other risks detailed in Part II, Item 1A "Risk Factors" of this Quarterly Report on Form 10-Q. We have implemented proactive cash conservation initiatives, including delaying certain capital expenditures, reducing operating costs, and purchasing interest rate swaps to fix certain variable rate debt at lower interest rates. Based on past
34


Table of Contents

performance and current expectations, we believe our cash and cash equivalents, cash generated from operations, and remaining funds available under our Revolver, will be sufficient to meet our working capital needs, capital expenditures, scheduled debt and interest payments, income tax obligations, and other currently anticipated liquidity requirements for at least the next 12 months.
However, as the impact of the COVID-19 pandemic on the economy and our operations evolves, we will continue to assess our liquidity needs. A continued worldwide disruption could materially affect our future access to sources of liquidity, particularly our cash flows from operations, and financial condition. In the event of a sustained market deterioration, we may need additional liquidity, which would require us to evaluate available alternatives and take appropriate actions.
Indebtedness
As of March 31, 2020, we had approximately $2.97 billion of total principal indebtedness (including $49.1 million in finance lease obligations), consisting of $2.35 billion in term loan debt, $300.0 million under our Revolver, and $275.0 million in borrowings against the accounts receivable financing agreement.
Credit Agreement
We are party to a credit agreement (as amended, the "Credit Agreement") for: (i) a $1.55 billion Term Loan A facility that matures on March 26, 2024 (“Term Loan A”); (ii) a $1.60 billion Term Loan B facility that matures on August 1, 2024 (“Term Loan B”); and (iii) a $600.0 million Revolver that matures on March 26, 2024.
During the three months ended March 31, 2020, we did not make any voluntary prepayments against Term Loans A or B. As a result of previous voluntary prepayments, we are not required to make a mandatory payment against the Term Loan B principal balance until maturity in August 2024. Additionally, during the three months ended March 31, 2020, we were not required to make any mandatory principal payments towards Term Loan A.
In February 2020, as a result of our Secured Leverage Ratio (as defined in the Credit Agreement) being less than or equal to 2.75x, the Adjusted Eurocurrency Rate Spread (as defined in the Credit Agreement) on our Term B Loans decreased from 2.00% to 1.75%.
In March 2020, we drew $300.0 million on our Revolver.
Our ability to make payments on our indebtedness and to fund planned capital expenditures and necessary working capital will depend on our ability to generate cash in the future. Our ability to meet our cash needs through cash flows from operations will depend on the demand for our services, as well as general economic, financial, competitive, and other factors, many of which are beyond our control, including the broad effects of the COVID-19 pandemic on the global economy and major financial markets. Our business may not generate cash flow in an amount sufficient to enable us to pay the principal of, or interest on, our indebtedness, or to fund our other liquidity needs, including working capital, capital expenditures, acquisitions, investments, and other general corporate requirements. If we cannot fund our liquidity needs, we will have to take actions such as reducing or delaying capital expenditures, acquisitions or investments, selling assets, restructuring or refinancing our debt, reducing the scope of our operations and growth plans, or seeking additional capital. We cannot assure you that any of these remedies could, if necessary, be affected on commercially reasonable terms, or at all, or that they would permit us to meet our scheduled debt service obligations. Our Credit Agreement contains covenant restrictions that limit our ability to direct the use of proceeds from any disposition of assets and, as a result, we may not be allowed to use the proceeds from any such dispositions to satisfy all current debt service obligations.


35


Table of Contents

Debt Covenants
Our Credit Agreement contains usual and customary restrictive covenants. Our Credit Agreement requires us to maintain a maximum First Lien Leverage Ratio (as defined in the Credit Agreement) of no more than 4.5 to 1.0 as of the last day of each fiscal quarter from and after March 31, 2020. We were in compliance with all applicable debt covenants as of March 31, 2020.
Letters of Credit
Our Revolver includes LOCs with a sublimit of $150.0 million. As of March 31, 2020, we had $300.0 million of outstanding Revolver borrowings and $19.2 million of LOCs outstanding, leaving $280.8 million in available borrowings under our Revolver, including $130.8 million available for LOCs.
Accounts Receivable Financing Agreement
We have an accounts receivable financing agreement (as amended) under which we can borrow up to $275.0 million from a third-party lender, secured by liens on certain receivables and other assets, with a termination date of September 30, 2021, unless terminated earlier pursuant to its terms. As of March 31, 2020, we had $275.0 million of outstanding borrowings under this agreement with no remaining borrowing capacity available.
Interest Rates
We have entered into various interest rate swaps to mitigate our exposure to changes in interest rates on our term loans. As of March 31, 2020, the percentage of our total principal debt (excluding leases) that is subject to fixed interest rates was approximately 54.4%. Each quarter-point increase or decrease in the applicable floating interest rate at March 31, 2020, would change our annual interest expense by approximately $3.3 million.
Stock Repurchase Program
On February 26, 2018, our Board of Directors ("Board") authorized the repurchase of up to an aggregate of $250.0 million of our common stock to be executed from time to time in open market transactions effected through a broker at prevailing market prices, in block trades, or privately negotiated transactions through December 31, 2019 (the "stock repurchase program"). On December 5, 2019, our Board approved an expansion and extension of the stock repurchase program. The Board increased the share repurchase authorization of our common stock to $300.0 million and extended the term of the program to December 31, 2020. We intend to use cash on hand and future free cash flow to fund the stock repurchase program.
We are not obligated to repurchase any particular amount of our common stock, and the stock repurchase program may be modified, extended, suspended, or discontinued at any time. The timing and amount of repurchases is determined by our management based on a variety of factors such as our corporate requirements for cash, overall market conditions, and the market price of our common stock. The stock repurchase program is subject to applicable legal requirements, including federal and state securities laws and applicable Nasdaq rules.
36


Table of Contents

The following table sets forth repurchase activity under the stock repurchase program from inception through March 31, 2020:
Total number of shares purchased Average price
paid per share 		Approximate dollar value of shares purchased (in thousands)
March 2018 948,100    $ 39.55    $ 37,493   
April 2018 1,024,400    36.60    37,492   
January 2019 552,100    39.16    21,623   
February 2019 120,600    41.40    4,993   
June 2019 509,100    45.29    23,055   
August 2019 141,100    49.93    7,045   
March 2020 600,000    53.38    32,029   
Total 3,895,400 $ 163,730   
As of March 31, 2020, we had remaining authorization to repurchase up to approximately $136.3 million of shares of our common stock under the stock repurchase program.
Cash, Cash Equivalents and Restricted Cash
Our cash flows from operating, investing, and financing activities were as follows (in thousands):
Three Months Ended March 31,
2020 2019 Change
Net cash used in operating activities $ (38,607)   $ (13,306)   $ (25,301)  
Net cash used in investing activities (18,620)   (11,445)   (7,175)  
Net cash provided by (used in) financing activities 229,918    (26,338)   256,256   
Cash Flows from Operating Activities
Cash flows from operating activities decreased by $25.3 million during the three months ended March 31, 2020, compared to the three months ended March 31, 2019. The decrease is primarily due to changes in operating assets and liabilities partially offset by higher cash-related net income. Fluctuations in accounts receivable, unbilled services (including contract assets), and deferred revenue occur on a regular basis as we perform services, achieve milestones or other billing criteria, send invoices to customers and collect outstanding accounts receivable. This activity varies by individual customer and contract. We attempt to negotiate payment terms that provide for payment of services prior to or soon after the provision of services, but the levels of accounts receivable, unbilled services (including contract assets), and deferred revenue can vary significantly from period to period. The impacts of the COVID-19 pandemic may also result in lower cash flow from operating activities during 2020 as a result of the anticipated impacts on our revenue and costs.
As a result of our integration activities associated with the Merger and our acquisition activity, we have incurred substantial expenses that have negatively impacted our cash flow from operating activities. For example, during the three months ended March 31, 2020, we incurred $11.7 million of expenses that impacted our operating cash flows in the current period or will impact operating cash flows in the future. We anticipate that we will continue to incur costs related to our integration efforts.
Cash Flows from Investing Activities
For the three months ended March 31, 2020, we used $18.6 million in cash for investing activities, which consisted of $11.9 million for purchases of property and equipment and $6.8 million for investments in unconsolidated affiliates. We continue to closely monitor our capital expenditures, especially in light of the COVID-19 pandemic, while making strategic investments in the development of our information
37


Table of Contents

technology infrastructure to meet the needs of our workforce, enable efficiencies, reduce business continuity risks, and conform to changes in governing rules and regulations.
For the three months ended March 31, 2019, we used $11.4 million in cash for investing activities, primarily for the purchase of property and equipment.
Cash Flows from Financing Activities
For the three months ended March 31, 2020, our financing activities provided $229.9 million in cash for financing activities, which consisted primarily of our $300.0 million draw down of our Revolver partially offset by repurchases of our common stock and contingent consideration payments.
For the three months ended March 31, 2019, we used $26.3 million in cash for financing activities, which consisted primarily of repayments of term loan debt and payments for the repurchase of our common stock. These payments were partially offset by proceeds from issuance of long-term debt and proceeds from our accounts receivable financing agreement.
Contractual Obligations and Commitments
Except for the $300.0 million draw on our Revolver, there have been no material changes during the three months ended March 31, 2020, outside of the ordinary course of business, to our contractual obligations as previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019.
Critical Accounting Policies and Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities, revenues, and expenses during the period, as well as disclosures of contingent assets and liabilities at the date of the financial statements. We evaluate our estimates on an ongoing basis, including those related to revenue recognition, share-based compensation, valuation of goodwill and identifiable intangibles, tax-related contingencies and valuation allowances, allowance for doubtful accounts, and litigation contingencies, among others. These estimates are based on the information available to management at the time these estimates, judgments, and assumptions are made. Actual results may differ materially from these estimates. Except as set forth below, there have been no significant changes to our critical accounting policies and estimates. For additional information on all of our critical accounting policies and estimates, refer to Part II - Item 7 - Management’s Discussion and Analysis included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019.
Goodwill and Intangible Assets
Goodwill represents the excess of purchase price over the estimated fair value of net assets acquired, including the amount assigned to identifiable intangible assets, in business combinations. In accordance with ASC Topic 350, Intangibles - Goodwill and Other, goodwill is not subject to amortization but must be tested for impairment annually or more frequently if events or changes in circumstances indicate that goodwill might be impaired. Goodwill is tested for impairment at the reporting unit level, which is one level below the operating segment level. This test requires us to determine if the implied fair value of the reporting unit's goodwill is less than its carrying amount.
The impairment analysis requires significant judgments, estimates and assumptions. There is no assurance that the actual future earnings or cash flows of the reporting units will not decline significantly from the projections used in the impairment analysis. Goodwill impairment charges may be recognized in future periods in one or more of the reporting units to the extent changes in factors or circumstances occur, including deterioration in the macroeconomic environment, industry, deterioration in our performance or future projections, or changes in plans for one or more of our reporting units. Specifically, the broad impacts of the COVID-19 pandemic may contribute to the potential impairment of the carrying value of our goodwill and definite-lived assets in the future.
38


Table of Contents

We completed our annual impairment test for potential impairment as of October 1, 2019 for all five of our reporting units, determining that there were no impairments. Our goodwill is principally related to the Merger completed on August 1, 2017. During the three months ended March 31, 2020, we evaluated whether a triggering event had occurred because of the broad impacts of the COVID-19 pandemic. We expect the COVID-19 pandemic will negatively impact our full year 2020 results of operations. However, at this time, we do not believe there has been a significant change in the long-term fundamentals of our business. Therefore, we have concluded a triggering event did not occur during the three months ended March 31, 2020. Depending on the extent to which future developments negatively impact our results of operations or financial outlook, an interim impairment test may be required in the future.
Intangible assets consist of backlog, customer relationships, and trademarks. We amortize intangible assets related to customer relationships and trademarks on a straight-line basis over the estimated useful life of the asset. Intangible assets related to backlog are amortized based on our expectations of the timing of when revenue associated with the backlog is expected to be recognized.
We review intangible assets at the end of each reporting period to determine if facts and circumstances indicate that the useful life is shorter than originally estimated or that the carrying amount of the assets might not be recoverable. If such facts and circumstances exist, we assess the recoverability of identified assets by comparing the projected undiscounted net cash flows associated with the related asset or group of assets over their remaining lives to their respective carrying amounts. Impairments, if any, are based on the excess of the carrying amount over the fair value of those assets and occur in the period in which the impairment determination is made. During the three months ended March 31, 2020, we evaluated whether a triggering event had occurred because of the broad impacts of the COVID-19 pandemic. We expect the COVID-19 pandemic will negatively impact our full year 2020 results of operations. However, at this time, we do not believe there has been a significant change in the long-term fundamentals of our business. We have concluded a triggering event did not occur during the three months ended March 31, 2020, and, as a result, no interim impairment testing was required. We will continue to evaluate the impacts of the COVID-19 pandemic on our business. Depending on the extent to which future developments negatively impact our results of operations and financial outlook, an
interim impairment test may be required in the future.
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
Except for the broad effects of the COVID-19 pandemic on the global economy and major financial markets, there have been no material changes to our quantitative and qualitative disclosures about market risk as compared to the quantitative and qualitative disclosures about market risk described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019.
39


Table of Contents

Item 4. Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our CEO and CFO, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, our CEO and CFO have concluded that as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.
In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.
Changes in Internal Controls
There have been no changes in our internal control over financial reporting identified in management’s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act during the period covered by this Quarterly Report on Form 10-Q that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

40


Table of Contents

PART II. OTHER INFORMATION
Item 1. Legal Proceedings.
We are party to legal proceedings incidental to our business. While our management currently believes the ultimate outcome of these proceedings, individually and in the aggregate, will not have a material adverse effect on our consolidated financial statements, litigation is subject to inherent uncertainties. Were an unfavorable ruling to occur, there exists the possibility of a material adverse impact on our financial condition and results of operations.
On December 1, 2017, the first of two virtually identical actions alleging federal securities law claims was filed against us and certain of our officers on behalf of a putative class of our shareholders. The first action, captioned Bermudez v. INC Research, Inc., et al, No. 17-09457 (S.D.N.Y.) in the Southern District of New York, names as defendants us, Michael Bell, Alistair MacDonald, Michael Gilbertini, and Gregory S. Rush (the "Bermudez action"), and the second action, Vaitkuvienë v. Syneos Health, Inc., et al, No. 18-0029 (E.D.N.C.) in the Eastern District of North Carolina, filed on January 25, 2018 (the "Vaitkuvienë action"), names as defendants us, Alistair MacDonald, and Gregory S. Rush (the "Initial Defendants"). Both complaints allege similar claims under Section 10(b) and Section 20(a) of the Securities Exchange Act of 1934 on behalf of a putative class of purchasers of our common stock between May 10, 2017 and November 8, 2017 and November 9, 2017. The complaints allege that we published inaccurate or incomplete information regarding, among other things, the financial performance and business outlook for inVentiv’s business prior to the Merger and with respect to the combined company following the Merger. On January 30, 2018, two alleged shareholders separately filed motions seeking to be appointed lead plaintiff and approving the selection of lead counsel. On March 30, 2018, Plaintiff Bermudez filed a notice of voluntary dismissal of the Bermudez action, without prejudice, and as to all defendants. On May 29, 2018, the Court in the Vaitkuvienë action appointed the San Antonio Fire & Police Pension Fund and El Paso Firemen & Policemen’s Pension Fund as Lead Plaintiffs and, on June 7, 2018, the Court entered a schedule providing for, among other things, Lead Plaintiffs to file an amended complaint by July 23, 2018 (later extended to July 30, 2018). Lead Plaintiffs filed their amended complaint on July 30, 2018, which also includes a claim against the Initial Defendants, as well as each member of the board of directors at the time of the INC Research - inVentiv Health merger vote in July 2017 (the “Defendants”), contending that the inVentiv merger proxy was misleading under Section 14(a) of the Act. Lead Plaintiffs seek, among other things, orders (i) declaring that the lawsuit is a proper class action and (ii) awarding compensatory damages in an amount to be proven at trial, including interest thereon, and reasonable costs and expenses incurred in this action, including attorneys’ fees and expert fees, to Lead Plaintiffs and other class members. Defendants filed a Motion to Dismiss Plaintiffs’ Amended Complaint on September 20, 2018. Lead Plaintiffs filed a Response in Opposition to such motion on November 21, 2018, and Defendants filed a Reply to such response on December 5, 2018. On May 23, 2019, Lead Plaintiffs filed a Notice of Filings in Related Case regarding the New Jersey shareholder action filed on March 1, 2019 described below, pending before the United States District Court for the District of New Jersey (the “New Jersey Action”), and Defendants filed their response on May 31, 2019. On September 26, 2019, the Court ordered, among other things, that this action is stayed in light of the New Jersey Action. On March 23, 2020, Defendants filed a Notice of Disposition of a Related Action, notifying the Court that the New Jersey Action was dismissed and requesting that the stay in this action should be lifted. We and the other defendants deny the allegations in these complaints and intend to defend vigorously against these claims.
On March 1, 2019, a complaint was filed in the United States District Court for the District of New Jersey on behalf of a putative class of shareholders who purchased our common stock during the period between May 10, 2017 and February 27, 2019. The action, captioned Murakami v. Syneos Health, Inc. et al, No. 19-7377 (D.N.J.), named us and certain of our executive officers as defendants and alleged violations of the Securities Exchange Act of 1934, as amended, based on allegedly false or misleading statements about our business, operations, and prospects. The plaintiffs sought awards of compensatory damages, among other relief, and their costs and attorneys’ and experts’ fees. On March 28, 2019, Lead Plaintiffs in the Vaitkuvienë action filed a motion to intervene and to transfer this action to the Eastern District of North Carolina, and we filed our response on April 22, 2019. On April 30, 2019, a shareholder filed a motion seeking to be appointed lead plaintiff and approving the selection of lead counsel. On October 16, 2019, the Court ordered that Plaintiff, by November 8, 2019, file proof of service of the
41


Table of Contents

Complaint in Compliance with Rule 4, or otherwise show cause why the action should not be dismissed for failure to properly serve Defendants (the "Order to Show Cause"). The Court further ordered that the action is stayed and that both motions are administratively terminated pending the Court's resolution of the Order to Show Cause. Plaintiff filed a response to the Order to Show Cause on November 8, 2019, and we and the other defendants filed a response on November 20, 2019. On March 20, 2020, the Court dismissed this action without prejudice for failure to serve defendants within the time period required by law.

42


Table of Contents

Item 1A. Risk Factors.
Other than the following risk factor, there have been no significant changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2019. Refer to “Risk Factors” in Part 1, Item 1A of that report for a detailed discussion of risk factors affecting us.
The COVID-19 pandemic is expected to adversely impact our business and results of operations.
On March 11, 2020, the World Health Organization designated the outbreak of the novel strain of coronavirus known as COVID-19 as a global pandemic. Governments around the world have taken unprecedented actions to mitigate the spread of COVID-19, including stay-at-home orders, quarantine requirements, and limitations on travel, including the closing of national borders. As a result of these restrictions, most of our employees are working remotely where possible and we have limited employee travel.
As a result of the COVID-19 pandemic, we have experienced and may continue to experience disruptions that could severely impact our business and our operations, including:
•delays or difficulties in commencing new and operating ongoing clinical trials, including the inability to access investigative sites, delays in enrolling patients and difficulty obtaining necessary pharmaceutical products and supplies;
•restrictions on the ability of our field teams within the Commercial Solutions segment to visit healthcare providers and delays in the commencement of new customer projects in that segment;
•diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials, as well as the reduction of our customers' operating budgets;
•interruption of key clinical trial activities, such as clinical trial site data monitoring, due to stay-at-home orders imposed or recommended by federal or state governments, employers, and others or interruption of clinical trial subject visits and study procedures;
•shutdowns or other business disruptions at our customers;
•limitations on our employee resources, including because of stay-at-home orders from federal or state governments, sickness of employees or their families or the desire of employees to avoid contact with large groups of people;
•diversion of management resources to focus on mitigating the impacts of the COVID-19 pandemic; and
•impacts from prolonged remote work arrangements, such as strains on our business continuity plans, cybersecurity risks, and inability of certain employees to perform their work remotely.
We currently expect that these disruptions will negatively impact our results of operations for the year ending December 31, 2020. The COVID-19 pandemic continues to evolve rapidly. The extent to which the pandemic will impact our business, liquidity and financial results will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate duration and severity of the pandemic; travel restrictions and social distancing requirements in the countries where we conduct business; the effectiveness of actions taken to contain and treat the disease; and how quickly and to what extent more normalized economic and operating conditions can resume. If we or our customers experience prolonged shutdowns or other business disruptions beyond current expectations, our ability to conduct our business could be materially and adversely impacted, and our business, liquidity, and financial results may be adversely affected.

43


Table of Contents

The continued spread of COVID-19 has led to disruption and volatility in the global capital markets, which increases the cost of, and adversely impacts access to, capital and increases economic uncertainty. This volatility and uncertainty have adversely affected our stock price, and may continue to do so. The actions that governments and individuals have taken in response to COVID-19 have led to a sharp contraction in many aspects of the United States economy and a steep rise in unemployment. The pandemic may cause an economic slowdown of potentially extended duration, and it is possible that it could cause a global recession. If this occurs, it could reduce our customer’s operating budgets or drive them to internally perform the clinical development and commercialization tasks that we provide, in which case our business would suffer. Even after the COVID-19 pandemic has subsided, we may continue to experience material adverse effects to our business as a result of the global economic impact of the pandemic.
Item 2. Unregistered Sales of Equity Securities, Use of Proceeds, and Issuer Purchases of Equity Securities.
Recent Sales of Unregistered Securities
Not applicable.
Purchases of Equity Securities by the Issuer
During the three months ended March 31, 2020, we repurchased 600,000 shares of our Class A common stock under our previously announced stock repurchase program described below, for a total of approximately $32.0 million. As of March 31, 2020, we have remaining authorization to repurchase up to approximately $136.3 million of shares of our Class A common stock under the stock repurchase program.
Period Total number of shares purchased Average price paid per share Total number of shares purchased as part of publicly announced plans or programs (1) Approximate dollar value of shares that may yet be purchased under the plans or programs (in thousands)
January 1, 2020 - January 31, 2020 —    $ —    —    $ 168,299   
February 1, 2020 - February 29, 2020 —    $ —    —    $ 168,299   
March 1, 2020 - March 31, 2020 600,000    $ 53.38    600,000    $ 136,270   
  Total 600,000    600,000   
(1) On February 26, 2018, the Board authorized the repurchase of up to an aggregate of $250.0 million of our Class A common stock, par value $0.01 per share, from time to time in open market transactions effected through a broker at prevailing market prices, in block trades, or privately negotiated transactions through December 31, 2019 (the "stock repurchase program"). The stock repurchase program commenced on March 1, 2018. On December 5, 2019, the Board increased the dollar amount authorized under the stock repurchase program to an aggregate of $300.0 million and extended the term of the program to December 31, 2020. We intend to use cash on hand and future free cash flow to fund the stock repurchase program. The stock repurchase program does not obligate us to repurchase any particular amount of our Class A common stock, and may be modified, extended, suspended, or discontinued at any time. The timing and amount of repurchases is determined by our management based on a variety of factors such as the market price of our Class A common stock, our corporate requirements, and overall market conditions. The stock repurchase program is subject to applicable legal requirements, including federal and state securities laws. We may also repurchase shares of our Class A common stock pursuant to a trading plan meeting the requirements of Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, which would permit shares of our Class A common stock to be repurchased when we might otherwise be precluded from doing so by law.
We immediately retired all of the repurchased common stock and charged the par value of the shares to common stock. The excess of the repurchase price over the par value was applied on a pro rata basis against additional paid-in capital, with the remainder applied to accumulated deficit.
44


Table of Contents

Item 5. Other Information.
Not applicable.
45


Table of Contents


Item 6. Exhibits
    Incorporated by Reference (Unless Otherwise Indicated)
Exhibit Number    Exhibit Description Form File No. Exhibit Filing Date    
10.1 —    —    —    Filed herewith
10.2 —    —    —    Filed herewith
10.3 8-K    001-36730    10.1    April 22, 2020
10.4 8-K    001-36730    10.2    April 22, 2020
10.5 8-K    001-36730    10.3    April 22, 2020
10.6 8-K    001-36730    10.4    April 22, 2020
10.7 8-K    001-36730    10.5    April 22, 2020
10.8 —    —    —    Filed herewith
31.1 —    —    —    Filed herewith
31.2 —    —    —    Filed herewith
32.1 —    —    —    Furnished herewith
32.2 —    —    —    Furnished herewith
101.INS Inline XBRL Instance Document - the Instance Document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document. —    —    —    Filed herewith
101.SCH Inline XBRL Taxonomy Extension Schema Document. —    —    —    Filed herewith
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document. —    —    —    Filed herewith
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document. —    —    —    Filed herewith
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document. —    —    —    Filed herewith
101.PRE Inline Taxonomy Extension Presentation Linkbase Document. —    —    —    Filed herewith
104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). —    —    —    Filed herewith

46


Table of Contents


SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
SYNEOS HEALTH, INC.
Date: April 29, 2020 BY: /s/ Jason Meggs
Jason Meggs
Chief Financial Officer
(Principal Financial Officer)


47

Exhibit 10.1

EXECUTION VERSION
EIGHTH AMENDMENT TO THE
RECEIVABLES FINANCING AGREEMENT

This EIGHTH AMENDMENT TO THE RECEIVABLES FINANCING AGREEMENT (this “Amendment”), dated as of March 18, 2020, is entered into by and among the following parties:
(i) SYNEOS HEALTH RECEIVABLES LLC, as Borrower;
(ii) SYNEOS HEALTH, LLC (f/k/a INC RESEARCH, LLC), as initial Servicer; and
(iii) PNC BANK, NATIONAL ASSOCIATION (“PNC”), as Administrative Agent and as lender.
Capitalized terms used but not otherwise defined herein (including such terms used above) have the respective meanings assigned thereto in the Receivables Financing Agreement described below.
BACKGROUND
A. The parties hereto have entered into a Receivables Financing Agreement, dated as of June 29, 2018 (as amended, restated, supplemented or otherwise modified through the date hereof, the “Receivables Financing Agreement”).
B. The parties hereto desire to amend the Receivables Financing Agreement as set forth herein.
NOW THEREFORE, with the intention of being legally bound hereby, and in consideration of the mutual undertakings expressed herein, each party to this Amendment hereby agrees as follows:
SECTION 1. Amendments to the Receivables Financing Agreement. The Receivables Financing Agreement is hereby amended to incorporate the changes shown on the marked pages of the Receivables Financing Agreement attached hereto as Exhibit A.
SECTION 2. Representations and Warranties of the Borrower and the Servicer. The Borrower and the Servicer hereby represent and warrant to each of the parties hereto as of the date hereof as follows:
(a) Representations and Warranties. The representations and warranties made by it in the Receivables Financing Agreement and each of the other Transaction Documents to which it is a party are true and correct as of the date hereof.
(b) Enforceability. The execution and delivery by it of this Amendment, and the performance of its obligations under this Amendment, the Receivables Financing Agreement (as amended hereby) and the other Transaction Documents to which it is a party are within its organizational powers and have been duly authorized by all necessary


action on its part, and this Amendment, the Receivables Financing Agreement (as amended hereby) and the other Transaction Documents to which it is a party are (assuming due authorization and execution by the other parties thereto) its valid and legally binding obligations, enforceable in accordance with their terms, except (i) as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws affecting the enforcement of creditors’ rights generally and (ii) as such enforceability may be limited by general principles of equity, regardless of whether such enforceability is considered in a proceeding in equity or at law.
(c) No Event of Default. After giving effect to this Amendment, no Event of Default or Unmatured Event of Default has occurred and is continuing, or would occur as a result of this Amendment or the transactions contemplated hereby.
SECTION 3. Effect of Amendment; Ratification. All provisions of the Receivables Financing Agreement and the other Transaction Documents, as expressly amended and modified by this Amendment, shall remain in full force and effect. After this Amendment becomes effective, all references in the Receivables Financing Agreement (or in any other Transaction Document) to “this Receivables Financing Agreement”, “this Agreement”, “hereof”, “herein” or words of similar effect referring to the Receivables Financing Agreement shall be deemed to be references to the Receivables Financing Agreement as amended by this Amendment. This Amendment shall not be deemed, either expressly or impliedly, to waive, amend or supplement any provision of the Receivables Financing Agreement other than as set forth herein. The Receivables Financing Agreement, as amended by this Amendment, is hereby ratified and confirmed in all respects.
SECTION 4. Effectiveness. This Amendment shall become effective as of the date hereof, subject to the conditions precedent that the Administrative Agent shall have received the following:
(a) counterparts to this Amendment executed by each of the parties hereto; and
(b) such opinions of counsel, certificates, resolutions and other deliverables, in each case, in form and substance acceptable to the Administrative Agent as may be reasonably requested by the Administrative Agent prior to the date hereof.
SECTION 5. Severability. Any provisions of this Amendment which are prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.
SECTION 6. Transaction Document. This Amendment shall be a Transaction Document for purposes of the Receivables Financing Agreement.


SECTION 7. Counterparts. This Amendment may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and all of which when taken together shall constitute one and the same agreement. Delivery of an executed counterpart hereof by facsimile or other electronic means shall be equally effective as delivery of an originally executed counterpart.
SECTION 8. GOVERNING LAW AND JURISDICTION.
(a) THIS AMENDMENT, INCLUDING THE RIGHTS AND DUTIES OF THE PARTIES HERETO, SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK (INCLUDING SECTIONS 5-1401 AND 5-1402 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK, BUT WITHOUT REGARD TO ANY OTHER CONFLICTS OF LAW PROVISIONS THEREOF).
(b) EACH PARTY HERETO HEREBY IRREVOCABLY SUBMITS TO (I) WITH RESPECT TO THE BORROWER AND THE SERVICER, THE EXCLUSIVE JURISDICTION, AND (II) WITH RESPECT TO EACH OF THE OTHER PARTIES HERETO, THE NON-EXCLUSIVE JURISDICTION, IN EACH CASE, OF ANY NEW YORK STATE OR FEDERAL COURT SITTING IN NEW YORK CITY, NEW YORK IN ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AMENDMENT, AND EACH PARTY HERETO HEREBY IRREVOCABLY AGREES THAT ALL CLAIMS IN RESPECT OF SUCH ACTION OR PROCEEDING (I) IF BROUGHT BY THE BORROWER, THE SERVICER OR ANY AFFILIATE THEREOF, SHALL BE HEARD AND DETERMINED, AND (II) IF BROUGHT BY ANY OTHER PARTY TO THIS AMENDMENT, MAY BE HEARD AND DETERMINED, IN EACH CASE, IN SUCH NEW YORK STATE COURT OR, TO THE EXTENT PERMITTED BY LAW, IN SUCH FEDERAL COURT. NOTHING IN THIS SECTION 8 SHALL AFFECT THE RIGHT OF THE ADMINISTRATIVE AGENT OR ANY OTHER CREDIT PARTY TO BRING ANY ACTION OR PROCEEDING AGAINST THE BORROWER OR THE SERVICER OR ANY OF THEIR RESPECTIVE PROPERTY IN THE COURTS OF OTHER JURISDICTIONS. EACH OF THE BORROWER AND THE SERVICER HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT IT MAY EFFECTIVELY DO SO, THE DEFENSE OF AN INCONVENIENT FORUM TO THE MAINTENANCE OF SUCH ACTION OR PROCEEDING. THE PARTIES HERETO AGREE THAT A FINAL JUDGMENT IN ANY SUCH ACTION OR PROCEEDING SHALL BE CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE JUDGMENT OR IN ANY OTHER MANNER PROVIDED BY LAW.
SECTION 9. Section Headings. The various headings of this Amendment are included for convenience only and shall not affect the meaning or interpretation of this Amendment, the Receivables Financing Agreement or any provision hereof or thereof.
[Signature pages follow]



IN WITNESS WHEREOF, the parties hereto have executed this Amendment by their duly authorized officers as of the date first above written.

SYNEOS HEALTH RECEIVABLES LLC,
as the Borrower

By: /s/Robert Parks
Name: Robert Parks
Title: President


SYNEOS HEALTH, LLC,
as the Servicer


By: /s/Jason Meggs
Name: Jason Meggs
Title: Chief Financial Officer





PNC BANK, NATIONAL ASSOCIATION,
as Administrative Agent


By: /s/Christopher Blaney
Name: Christopher Blaney
Title: Senior Vice President
PNC BANK, NATIONAL ASSOCIATION,
as a Lender


By: /s/Christopher Blaney
Name: Christopher Blaney
Title: Senior Vice President





Exhibit A

(attached)



EXECUTION VERSION

EXHIBIT A to the EIGHTH AMENDMENT, dated as of March 18, 2020
CONFORMED COPY INCLUDES
FIRST AMENDMENT, dated as of August 1, 2018 SECOND AMENDMENT, dated as of August 29, 2018 THIRD AMENDMENT, dated as of October 25, 2018 FOURTH AMENDMENT, dated as of January 2, 2019 FIFTH AMENDMENT, dated as of July 25, 2019 SIXTH AMENDMENT, dated as of September 30, 2019
OMNIBUS AMENDMENT, dated as of January 31, 2020






RECEIVABLES FINANCING AGREEMENT

Dated as of June 29, 2018 by and among
SYNEOS HEALTH RECEIVABLES LLC,
as Borrower,

THE PERSONS FROM TIME TO TIME PARTY HERETO,
as Lenders,

PNC BANK, NATIONAL ASSOCIATION,
as Administrative Agent,

SYNEOS HEALTH, LLC,
as initial Servicer, and
PNC CAPITAL MARKETS LLC,
as Structuring Agent













736456321 18569090




“Commencement Date” means the date, if any, identified as the “Commencement Date” in a writing delivered by the Borrower to the Administrative Agent; provided, however, that the “Commencement Date” shall be deemed to be the date of the initial Credit Extension if not previously identified as a date on or prior to the date of the initial Credit Extension.

“Commitment” means, with respect to any Lender, the maximum aggregate amount of Capital which such Person is obligated to lend or pay hereunder on account of all Loans, on a combined basis, as set forth on Schedule I or in such other agreement pursuant to which it became a Lender, as such amount may be modified in connection with any subsequent assignment pursuant to Section 14.03 or in connection with a reduction in the Facility Limit pursuant to Section 2.02(e). If the context so requires, “Commitment” also refers to a Lender’s obligation to make Loans hereunder in accordance with this Agreement.

“Concentration Percentage” means (a) except as provided in clause (b) below, (i) for any Group A Obligor, 25.0%, (ii) for any Group B Obligor, 15.0%, (iii) for any Group C Obligor, 10.0% and (iv) for any Group D Obligor, 5.0%. and (b) for each of the Obligors listed in the chart below (each, a “Special Obligor”), the percentage specified in the chart below for such Special Obligor (the applicable “Special Concentration Limit”); provided, however, that (i) the Administrative Agent may, upon not less than five (5) Business Days’ written notice to the Borrower, cancel or reduce the Special Concentration Limit with respect to any or all Special Obligors and (ii) if the aggregate Outstanding Balance of Pool Receivables owing by any Special Obligor that constitute Delinquent Receivables exceeds 30.0% of the aggregate Outstanding Balance of all Pool Receivables owing by such Special Obligor, then the Special Concentration Limit with respect to such Special Obligor shall be immediately and automatically cancelled, and thereafter, in each case, the Concentration Percentage for such Special Obligor(s) shall be determined pursuant to clause (a) above. In the event that any other Obligor is or becomes an Affiliate of a Special Obligor, the Special Concentration Limit shall apply to both such Obligor and such Special Obligor and shall be calculated as if such Obligor and such Special Obligor were a single Obligor.

Special Obligor
Special Concentration Limit
Otsuka Pharmaceutical Development and Commercialization, Inc.
8.0%

“Concentration Reserve Percentage” means, at any time of determination, the largest of:
(a) the sum of the four (4) largest Obligor Percentages of the Group D Obligors, (b) the sum of the two (2) largest Obligor Percentages of the Group C Obligors and (c) the largest Obligor Percentage of the Group B Obligors.

“Contract” means, with respect to any Receivable, any and all contracts, instruments, agreements, leases, invoices, notes or other writings pursuant to which such Receivable arises or that evidence such Receivable or under which an Obligor becomes or is obligated to make payment in respect of such Receivable.

“Covered Entity” means (a) each of Borrower, the Servicer, each Originator, the Parent and each of the Parent’s Subsidiaries and (b) each Person that, directly or indirectly, is in control



736456321 18569090     8



financial institution, on behalf of Borrower, as originator and (iv) any other payment order drawn on or payable against any Collection Account.

“Settlement Item Amounts” means the face amount of each Settlement Item.

“Sixth Amendment Closing Date” means September 30, 2019.

“Solvent” means, with respect to any Person and as of any particular date, (i) the present fair market value (or present fair saleable value) of the assets of such Person is not less than the total amount required to pay the probable liabilities of such Person on its total existing debts and liabilities (including contingent liabilities) as they become absolute and matured, (ii) such Person is able to realize upon its assets and pay its debts and other liabilities, contingent obligations and commitments as they mature and become due in the normal course of business, (iii) such Person is not incurring debts or liabilities beyond its ability to pay such debts and liabilities as they mature and (iv) such Person is not engaged in any business or transaction, and is not about to engage in any business or transaction, for which its property would constitute unreasonably small capital after giving due consideration to the prevailing practice in the industry in which such Person is engaged.

“Special Concentration Limit” has the meaning set forth in the definition of Concentration Percentage.

        “Special Obligor” has the meaning set forth in the definition of Concentration Percentage.

“Sponsors” means, collectively, Advent, THL and Liberty Lane, their respective controlled Affiliates and funds managed or advised by any of them or any of their respective controlled Affiliates (in each case, other than any portfolio company).

“Stress Factor” means, at any time of determination, (i) if a Ratings Event has occurred and is continuing, 2.50 and (ii) otherwise, 2.00.

“Structuring Agent” means PNC Capital Markets LLC, a Pennsylvania limited liability company.

“Sub-Servicer” has the meaning set forth in Section 9.01(d).

“Subject Obligor” means Takeda Pharmaceutical Company Ltd.

“Subject Obligor Delinquency Trigger” shall have occurred as of any date of determination if 30% or more of the aggregate Outstanding Balance of all Pool Receivables, the Obligor of which is the Subject Obligor or any Affiliate thereof, constitute Delinquent Receivables as of such date.

“Subsidiary” means, as to any Person, a corporation, partnership, limited liability company or other entity of which shares of stock of each class or other interests having ordinary voting power (other than stock or other interests having such power only by reason of the happening of a contingency) to elect a majority of the Board of Directors or other managers of such entity are at the time owned, or management of which is otherwise controlled: (a) by such

736456321 18569090     30


(c) Any indemnification or contribution under this Section shall survive the
termination of this Agreement.

ARTICLE XIV

MISCELLANEOUS

SECTION 14.01. Amendments, Etc.

(a)No failure on the part of any Credit Party to exercise, and no delay in
exercising, any right hereunder shall operate as a waiver thereof; nor shall any single or partial exercise of any right hereunder preclude any other or further exercise thereof or the exercise of any other right. No amendment or waiver of any provision of this Agreement or consent to any departure by any of the Borrower or any Affiliate thereof shall be effective unless in a writing signed by the Administrative Agent and the Majority Lenders (and, in the case of any amendment, also signed by the Borrower), and then such amendment, waiver or consent shall be effective only in the specific instance and for the specific purpose for which given; provided, however, that (A) no amendment, waiver or consent shall, unless in writing and signed by the Servicer, affect the rights or duties of the Servicer under this Agreement; (B) no amendment, waiver or consent shall, unless in writing and signed by the Administrative Agent and each Lender:

(i)change (directly or indirectly) the definitions of, Borrowing Base
Deficit, Defaulted Receivable, Delinquent Receivable, Eligible Receivable, Facility Limit, Final Maturity Date, Net Receivables Pool Balance or Total Reserves contained in this Agreement, or increase the then existing Concentration Percentage or Special Concentration Limit for any Obligor or change the calculation of the Borrowing Base;

(ii)reduce the amount of Capital or Interest that is payable on account
of any Loan or with respect to any other Credit Extension or delay any scheduled date for payment thereof;

(iii)change any Event of Default;

(iv)release all or a material portion of the Collateral from the
Administrative Agent’s security interest created hereunder;

(v)release the Performance Guarantor from any of its obligations
under the Performance Guaranty or terminate the Performance Guaranty;

(vi)change any of the provisions of this Section 14.01 or the definition
of “Majority Lenders”; or

(vii)change the order of priority in which Collections are applied
pursuant to Section 4.01.

Notwithstanding the foregoing, (A) no amendment, waiver or consent shall increase any Lender’s Commitment hereunder without the consent of such Lender, (B) no amendment, waiver

736456321 18569090     95

Exhibit 10.2

Execution Version
AMENDMENT NO. 3

AMENDMENT NO. 3, dated as of April 7, 2020 (this “Amendment”) by and between SYNEOS HEALTH, INC., a Delaware corporation (the “Administrative Borrower”) and JPMORGAN CHASE BANK, N.A., as Administrative Agent for the Lenders (in such capacity, the “Administrative Agent”), relating to that certain Credit Agreement, dated as of August 1, 2017 (as amended by Amendment No. 1, dated as of May 4, 2018, and by Amendment No. 2, dated as of March 26, 2019, and as further amended, restated, amended and restated, supplemented or otherwise modified from time to time prior to the date hereof), among the Borrowers, the Lenders from time to time party thereto and the Administrative Agent (the “Credit Agreement”). Capitalized terms used and not otherwise defined in this Amendment have the meanings given to them in the Credit Agreement.
Pursuant to Section 9.02(d)(iii) of the Credit Agreement, the Administrative Agent and the Administrative Borrower agree as follows:

A. Amendment. Clause (m) of the definition of Excess Cash Flow in Section 1.01 of the Credit Agreement is hereby amended by replacing the reference to “clauses (b), (f) and/or (i) of the definition of “Consolidated Adjusted EBITDA”” with “clauses (b), (f) and/or (j) of the definition of “Consolidated Adjusted EBITDA.””
B. Effectiveness. Pursuant to Section 9.02(d)(iii) of the Credit Agreement, the Administrative Agent may, with the consent of the Administrative Borrower only, amend any ambiguity, mistake, defect, inconsistency, obvious error or any error or omission of a technical nature or any necessary or desirable technical change, in each case, jointly identified by the Administrative Agent and the Administrative Borrower, in any provision of any Loan Document solely to address such matter as reasonably determined by them acting jointly, without the consent of any Lender. The purpose and effect of this Amendment is to cure a defect in the Credit Agreement and does not adversely affect the rights of any Lender. Accordingly, this Amendment shall become effective on the date hereof (the “Amendment Effective Date”) upon execution by both the Administrative Agent and the Administrative Borrower, without any further action or consent of any other party to any Loan Document.
C.  Effect on the Credit Agreement and the Other Loan Documents. Except as specifically amended hereby, the Credit Agreement and the other Loan Documents shall remain in full force and effect and are hereby ratified and confirmed. The execution, delivery and performance of this Amendment shall not constitute a waiver of any provision of, or operate as a waiver of any right, power or remedy of the Administrative Agent or any Lender under, the Credit Agreement or any of the other Loan Documents. On and after the Amendment Effective Date, each reference in the Credit Agreement to “this Agreement”, “hereunder”, “hereof”, “herein” or words of like import referring to the Credit Agreement, and each reference in the other Loan Documents to the “Credit Agreement”, “thereunder”, “thereof” or words of like import referring to the Credit Agreement shall mean and be a reference to the Credit Agreement as amended by this Amendment.
D.  Applicable Law; Jurisdiction; Waiver of Jury Trial, Etc. THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK. THE OTHER PROVISIONS OF SECTIONS 9.10 (GOVERNING LAW; JURISDICTION; CONSENT TO SERVICE OF PROCESS) AND 9.11 (WAIVER OF JURY TRIAL) OF THE CREDIT AGREEMENT ARE HEREBY INCORPORATED BY REFERENCE, MUTATIS MUTANDIS.
[Signature pages follow]



Consented to and agreed as of the date first set forth above:


JPMORGAN CHASE BANK, N.A.,
as Administrative Agent


By: /s/ Antje Focke
Name: Antje Focke
Title: Executive Director
[Signature Page – Amendment No. 3]


Consented to and agreed as of the date first set forth above:

SYNEOS HEALTH, INC.,
as Administrative Borrower


By: /s/ Jason Meggs
Name: Jason Meggs
Title: Chief Financial Officer
[Signature Page – Amendment No. 3]


Exhibit 10.8


IMAGE11.JPG
INC Research UK Limited | Farnborough Business Park, 1 Pinehurst Road, Farnborough, Hampshire, GU14 7BF, United Kingdom
Registered in England and Wales No.: 04428083 T: +44 (0)1276 713000

3rd May 2019


Mr. A. MacDonald Via Email



Dear Alistair,

Following our recent communications, we are writing to confirm the following details of a change to contract due to the recent strategy to streamline the Syneos Health UK entities.

Effective 1st June 2019 the contract of employment terms will be amended as follows:

1. ENTITY

You will be aligned to the Syneos Health UK Limited Entity, No. 004.

All other terms and conditions of the original employment agreement remain in force. Yours Sincerely,
For and on behalf of Syneos Health UK Limited

IMAGE01.JPG


Stephanie Dickinson
Associate Director, Human Resources











© 2018 All rights reserved | Confidential | For Syneos HealthTM use only    syneoshealth.com | 1


Exhibit 31.1
CERTIFICATIONS
I, Alistair Macdonald, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of Syneos Health, Inc. (the “registrant”);
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: April 29, 2020
 
/s/ Alistair Macdonald
Alistair Macdonald
Chief Executive Officer
(Principal Executive Officer)



Exhibit 31.2
CERTIFICATIONS
I, Jason Meggs, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of Syneos Health, Inc. (the “registrant”);
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: April 29, 2020
 
/s/ Jason Meggs
Jason Meggs
Chief Financial Officer
(Principal Financial Officer)



Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
In accordance with 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Alistair Macdonald, Chief Executive Officer of Syneos Health, Inc. (the “registrant”), do hereby certify, that to the best of my knowledge:
1. The registrant's Quarterly Report on Form 10-Q for the period ended March 31, 2020, (the “Report”), to which this Certification is attached as Exhibit 32.1, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.

Date: April 29, 2020
 
/s/ Alistair Macdonald
Alistair Macdonald
Chief Executive Officer
(Principal Executive Officer)

This certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of the Report, irrespective of any general incorporation language contained in such filing.

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.




Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
In accordance with 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Jason Meggs, Chief Financial Officer of Syneos Health, Inc. (the “registrant”), do hereby certify, that to the best of my knowledge:
1. The registrant's Quarterly Report on Form 10-Q for the period ended March 31, 2020 (the “Report”), to which this Certification is attached as Exhibit 32.2, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.
 
Date: April 29, 2020
 
/s/ Jason Meggs
Jason Meggs
Chief Financial Officer
(Principal Financial Officer)

This certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of the Report, irrespective of any general incorporation language contained in such filing.

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.